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ABSTRACT 
Zhiwen Liu 
Severe Hypoglycemia, Risk of Recurrent Events and Weight Gain 
on Insulin Therapy in Patients with Type 1 Diabetes Mellitus 
(Under the direction of Til Stürmer, M.D., MPH) 
BACKGROUND: Few studies provide epidemiologic evidence to demonstrate acute effects 
of severe hypoglycemia (SH) on subsequent SH in patients with type 1 diabetes mellitus 
(T1DM) under a clinically relevant time range. Although it is well accepted that hypoglycemia 
could associate with subsequent weight gain in T1DM, there is limited direct evidence to 
support this hypothesis.  
METHODS: We conducted a secondary data analysis using data from the Diabetes Control 
and Complications Trial (DCCT) which randomized T1DM patients to either intensive (IT) or 
conventional therapy (CT) and followed them quarterly. We estimated relative risks (RR) for 
subsequent SH in three consecutive quarterly time windows following occurrence of SH 
(index SH). We estimated the effects of SH on subsequent weight change/weight (kg) in 
various observation periods. We used generalized estimating equations to account for the 
dependence of multiple-observations within a person and to adjust for confounding. Hazard 
ratios (HRs) of SH on substantial weight gain, overweight and obesity were estimated using 
Cox and marginal structural models. 
RESULTS: in both treatment arms, the greatest absolute risks and RRs for subsequent SH 
after index SH were observed in the first time window in three consecutive quarterly 
windows following index SH. In IT, the estimated effect of SH on weight change/weight was 
close to null effect. In CT, a weight loss was observed during the 1st 3-month following SH 
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[adjusted difference of the means for weight change (MDWC) was -0.29 (-0.51, -0.08)] 
comparing to those without SH. The HRs of SH on substantial weight gain, becoming 
overweight or obese were also found around the null effect (HR=1) in both treatment arms. 
CONCLUSIONS: This study provides direct evidence to support an acute effect of recent 
SH on subsequent SH episodes, and the results indicate that the immediate time periods 
after occurrence of SH are crucial in clinical management of T1DM to prevent subsequent 
SH. We did not find evidence to support an association between occurrence of SH and 
subsequent weight gain in patients with T1DM. Because the DCCT is a clinical trial design, 
one should be cautious in extrapolating our findings to all patients with T1DM. 
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I. INTRODUCTION 
Hypoglycemia and weight gain are two primary adverse events during insulin therapy 
among patients with type 1 diabetes [1-4]. Hypoglycemia has been documented to be the 
leading limiting factor of intensive diabetes management among patients with type 1 
diabetes mellitus [5, 6]. Hypoglycemia also causes recurrent physical and psychological 
morbidity, higher risk of mortality and impairs defenses against subsequent hypoglycemia 
[1]. Although weight gain after initial insulin treatment is often perceived as desirable [4] in 
type 1 diabetes, excessive weight gain can not only increase diabetic morbidity and mortality 
when weight gain becomes a barrier to the intensification of insulin treatment, but also 
adversely affect cardiovascular risk profiles as well [4, 7].  
Severe hypoglycemia (SH) can induce the defect in counterregulation and loss of 
awareness of hypoglycemia under the mechanism of hypoglycemia-associated autonomic 
failure (HAAF)[1]. Thus, prior SH can cause a vicious cycle of recurrent hypoglycemia [2, 8], 
and the effect of SH episodes is often regarded as an acute effect that the greatest risk may 
occur in weeks and months after episodes of prior SH [1].  
Although prior studies have consistently reported prior SH as a risk factor in general 
for recurrent subsequent SH [9-16], epidemiological evidence which could provide 
information for clinical management of occurrence of SH in the patients with type 1 diabetes 
on insulin therapy has not been fully illustrated. Very few studies provide epidemiologic 
evidence to demonstrate the acute effects of SH on subsequent SH in a clinically relevant 
time range, and the magnitude of the effects from population levels in patients with type 1 
diabetes is not completely clear either.  
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A number of possible mechanisms have been described to explain weight gain on 
insulin therapy including compensation for hypoglycemia [4]. The unpleasant symptoms and 
negative consequences of hypoglycemia may result in significant fear of hypoglycemia [17]. 
Because low blood glucose levels can be remedied by ingestion of glucose or food, 
following a hypoglycemic event, patients may over-react or be instructed by consuming 
more calories (e.g., frequent snacking) in response to the threat of subsequent 
hypoglycemia. However, there is also very limited direct evidence to support this hypothesis 
of compensation for hypoglycemia. 
The objectives of this study are: 1) in a clinically relevant time range, to estimate and 
illustrate the acute effects of SH on risk of subsequent SH episodes in patients with type 1 
diabetes; 2) to provide insight into the interplay of two primary adverse events (SH and 
weight gain) in patients with type 1 diabetes. Eventually, the results should provide 
physicians with useful information to help them better clinically manage patients with type 1 
diabetes on insulin therapy to reduce recurrent SH and excessive weight gain. 
 
 
 
 
 
 
 
 
      
 
II. REVIEW OF THE LITERATURE 
A. Hypoglycemia in patients with type 1 Diabetes 
Hypoglycemia in insulin-treated patients has been documented to be the most 
common adverse effect and leading limiting factor of intensive diabetes management among 
type 1 diabetes mellitus [5, 6]. Hypoglycemia associated with insulin treatment also causes 
recurrent physical and psychological morbidity, mortality and impairs defenses against 
subsequent hypoglycemia [1]. Hypoglycemia has been classified as “asymptomatic” or 
“biochemical”, which is particularly common, and “symptomatic”. Symptoms of hypoglycemia 
may be idiosyncratic. Neurogenic symptoms often include palpitations, tremor, hunger, and 
sweating. Neuroglycopenic symptoms often include behavioral changes, difficulty thinking, 
and/or frank confusion, and neuroglycopentic manifestations can lead to seizure, coma, and 
even death [3].   
Hypoglycemia is regarded as a fact of life for most people with type 1 diabetes. It is 
estimated that the average patients with type 1 diabetes has untold numbers of episodes of 
asymptomatic hypoglycemia and suffers two episodes of symptomatic hypoglycemia per 
week [2]. Although severe hypoglycemia (SH), which requires the assistance of another 
individual, represents only a small fraction of the total hypoglycemia experience, it was 
estimated that the incidence of SH was around 115 episodes per 100 patient-years in a 
random sample of 267 people recruited from a population-based diabetes register in 
Scotland in 2001 [2]. Though the subjects in the DCCT trial (the Diabetes Control and 
Complication Trial) were highly selective and those who had multiple events of SH before 
enrollment were not eligible to participate [10, 18], almost half of the DCCT cohort still had 
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one or more episodes of hypoglycemia requiring assistance (severe hypoglycemia), and 
intensive therapy was associated with a threefold increase in the risk of SH compared with 
conventional therapy (the event rate per 100 patient-years was 61.2 in the intensive therapy 
versus 18.7 in the conventional therapy group). Unfortunately, there seems no evidence that 
this problem has abated over the decade and a half since it was highlighted by the final 
report of the DCCT in 1993 [2]. 
In people with type 1 diabetes, hypoglycemia is the result of the interplay of relative 
or absolute insulin excess and compromised physiological defenses against falling plasma 
glucose concentrations [1, 2]. The major conventional risk factors for hypoglycemia in type 1 
diabetes includes: relative insulin excess; aggressive glycemic therapy with more stringent 
control goals; impaired renal function; and patient behavioral activities such as missed 
meals or snacks, unusual exercise, altered insulin doses and alcohol use. However, these 
known behaviors as risk factors alone are believed to explain only a minority of episodes of 
hypoglycemia in patients with type 1 diabetes [2].  
Besides the above conventional risk factors, the concept of hypoglycemia-associated 
autonomic failure (HAAF) in diabetic patients posits that recent prior hypoglycemia as well 
as prior exercise and sleep can cause both defective glucose counterregulation (by reducing 
the epinephrine response and glucagon response) and hypoglycemia unawareness (by 
reducing sympathetic neural response) and thus those factors can cause a vicious cycle of 
recurrent hypoglycemia (Figure 1) [2, 8]. The risk factors for HFFA include the degree of 
absolute endogenous insulin deficiency; history of SH, hypoglycemia unawareness, or both 
as well as recent prior hypoglycemia, prior exercise, or sleep. Some studies suggest that 
two to three weeks of scrupulous avoidance of hypoglycemia should be a rational approach 
to reverse hypoglycemia unawareness and to improve glucose counterregulation [2, 19]. 
However, whether this approach can work in routine clinical practice is unknown because it 
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requires a labor-intensive approach with frequent, often daily, contact between health 
professionals and patients, frequent blood glucose monitoring and insulin adjustment to 
prevent episodes, particularly at night [19].  
 
 
Figure 1: Schematic diagram of HAAF in Diabetes 
(From Cryer PPE. The barrier of hypoglycemia in diabetes. Diabetes (New York, N.Y.). 
2008; 57(12):3169-3176) 
 
The prevention of hypoglycemia involves: acknowledging and addressing the 
problem; applying the principles of intensive glycemic therapy (diabetes self-management 
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based on patient education, frequent blood glucose monitoring and appropriate and flexible 
insulin regiments); considering both the conventional risk factors and the indicative of HAAF 
[19]. American Diabetes Association Workgroup on hypoglycemia concluded that any 
reduction in SH (that requiring the assistance of another individual), even by as little as 10-
20% would be advantageous. But the Workgroup also mentioned that a clinically important 
reduction in hypoglycemia should not be accompanied by any compromise in the glycemia 
control goals [20].  
B. Risk of prior SH on subsequent SH in type 1 diabetes 
SH can induce the defect in counterregulation and loss of awareness of 
hypoglycemia due to the HAFF, and the defect would increase the subsequent risk of 
recurrent SH in patients with type 1 diabetes [1]. Thus, prior SH could cause a vicious cycle 
of recurrent hypoglycemia [2, 8], and the effect of SH is often regarded as an acute effect 
that the greatest risk may occur in weeks and months after episodes of prior SH events [1].  
Studies have been consistently reported SH as a risk factor in general for recurrent 
SH events [9-16]. An early DCCT study, which followed a cohort of 817 patients with a mean 
of 21 months follow-up, reported a hazard ratio 2.5 (CI: 1.7-3.9) for the effect of history of 
SH before the DCCT baseline on the first subsequent SH event during the follow-up [9]. The 
later DCCT study which used all participants (1,441 patients) further reported that per 
additional episode of SH was associated with a hazard ratio 1.2 (CI: 1.2-1.2) on subsequent 
recurrent SH episodes in the conventional therapy group and 1.1 (CI: 1.1-1.1) in the 
intensive therapy group respectively during a mean 6.5 follow-up years [10]. Another cohort 
study using the same DCCT population also reported that history of SH prior to the DCCT 
baseline was associated with the first, second, third, fourth and fifth SH event during the 
follow-up with hazard ratios 2.0, 2.3, 2.4, 2.3 and 2.7, respectively [16]. Similarly, a German 
study prospectively followed a cohort of 684 patients with type 1 diabetes in an average 19 
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follow-up months and found the occurrence of SH in the preceding year prior to the study 
baseline was associated SH episodes which occurred during the follow-up with a hazard 
ratio 2.7 (CI: 1.8-4.3) [13]. Another German cohort study which followed 636 patients with 
type 1 diabetes also reported to find an association between the occurrence of SH in the 
previous year prior to the study baseline and the subsequent occurrence of SH during six 
follow-up years [12]. However, these two studies have used different definition of SH 
compared with the DCCT study. The SH was defined as being treated by glucagon injection 
reported by patients themselves in these two German studies whereas in the DCCT study, 
SH was defined as the need for assistance from others. 
Although above studies consistently have shown that the prior SH is a risk factor in 
general for the subsequent SH events, few studies estimated the magnitude of acute effects 
of SH using clinically relevant time range to define the exposure (prior SH) and outcome 
(subsequent SH events) to illustrate the acute effects of SH. One Scottish study which 
prospectively followed 94 patients with type 1 diabetes reported that the occurrence of 
hypoglycemia in the previous month was associated with the occurrence of hypoglycemia in 
next month with an odds ratio 4.6 (CI: 1.5-13.7) [15]. The effect appears greater in this study 
compared to estimates reported by other studies that did not restrict their definition of 
exposure and outcome to a short time range, and the results of this study seem to support 
the notion of an acute effect [1]. This study has its limitations however: first, the follow-up 
time was only one month and the sample is small; secondly, the definition of hypoglycemia 
is totally based on self-report by patients, and the investigators did not differentiate the 
severity of reported hypoglycemia; lastly, in this study, patients were asked to use a diary to 
record their hypoglycemic events after their baseline interview, and therefore those patients 
who reported hypoglycemic events in the baseline interview may tend to over-report the 
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hypoglycemic events in their one month follow-up. Thus, the greater effect reported by this 
study could be biased due to the study design.  
The epidemiological evidence, which can illustrate the acute effects of SH and 
provide the magnitude of the effects, will help to improve clinical management of SH in 
patients with type 1 diabetes (e.g., to help physicians to consider available interventions in 
appropriate timing to reduce subsequent SH events when a SH event has occurred).  
Table 1: Results from prior studies for the effects of severe hypoglycemia (SH) on 
subsequent SH events 
Authors/ 
Publication 
year 
Study population Results Comments 
The DCCT 
study 
group/1991 
First 817 subjects 
who entered the 
DCCT, with a mean 
of follow-up of 21 
months 
Hazard ratio for the effect of history of 
severe hypoglycemia (SH) at study 
baseline on the first occurrence of SH 
during the follow-up was 2.54 (CI: 1.67-
3.88) 
SH was defined as 
the hypoglycemic 
events requiring 
assistance from 
other people 
The DCCT 
study 
group/1997 
All subjects in the 
DCCT with a mean 
of follow-up 6.5 
years 
Hazard ratios for the effect of history of SH 
at study baseline on any occurrence of SH 
during the follow-up were 1.7 (CI: 1.36-
2.13) in the conventional therapy group 
and 1.33 (CI: 1.17-1.52) in the intensive 
therapy group. Per additional episode of 
SH during follow-up was associated with a 
hazard ratio 1.16 (CI: 1.15-1.18) in the 
conventional therapy group and 1.1 (CI: 
1.1-1.11) in the intensive therapy group 
SH was defined as 
the hypoglycemic 
events requiring 
assistance from 
other people 
Kilpatrick et 
al./2007 
All subjects in the 
DCCT with a mean 
of follow-up 6.5 
years 
History of SH at study baseline was 
associated with the first SH event, second, 
third, fourth and fifth event during the 
follow-up with hazard ratios 1.98, 2.27, 
2.36,2.31 and 2.64, respectively 
SH was defined as 
the hypoglycemic 
events requiring 
assistance from 
other people 
Mühlhauser I et 
al/1998 
684 patients from a 
German community 
with a mean of 
follow-up 19 months 
The occurrence of SH during the preceding 
12 months at the baseline was associated 
recurrent SH with a hazard ratio 2.73 (CI: 
1.76-4.25) 
SH was defined as 
being treated by 
glucagon injection 
reported by patients 
themselves 
Bott S et al/ 
1997 
636 patients from 
German hospitals 
with a mean of 6 
years 
The history of SH was associated with SH 
during the follow-up (P value 0.0007) 
SH was defined as 
being treated by 
glucagon injection 
reported by patients 
themselves 
Donnelly LA et 
al/2005 
94 patients in 
Scotland with one 
month follow-up 
The occurrence of hypoglycemia in the 
previous month was associated with the 
occurrence of hypoglycemia in next month 
with odd ratio 4.60 (CI: 1.54-13.68) 
The definition of 
hypoglycemia was 
totally based on 
self-report without 
differentiating 
severity of reported 
events. 
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C. Weight gain, and the role of hypoglycemia for weight gain during insulin treatment 
Improved glycemic control on insulin is often observed to be associated with weight 
gain [4, 21]. At diagnosis patients with type 1 diabetes may be underweight following a 
period of glucosuria, osmotic diuresis and frank catabolism due to lack of insulin. Thus 
weight gain after initializing insulin treatment is often regarded as normalization [4, 21]. 
However, in the DCCT patients in the intensive therapy group continued gaining weight up 
to 9 years although weight gain was less rapid after the first year [22].  The prevalence of 
overweight defined as the body mass index (BMI) over 27.8kg/m2 for men and 27.3kg/m2 for 
women in the DCCT study population reached 33% in the intensive therapy group and 19% 
in the conventional therapy group at the end of the DCCT [18].  
Furthermore, patients with excessive weight gain may have higher risk of 
cardiovascular diseases in future. Purnell et al. [7] stratified data in the intensive therapy 
group by quartiles of weight gain at the end of the DCCT. When they compared the first 
quartile (where BMI did not change appreciable) with the fourth quartile (where BMI 
increased by 7kg/m2), the baseline cardiovascular diseases profiles at the beginning of the 
trial were similar between these two quartiles, and at the end of the DCCT both quartiles 
also had similar A1C levels. However, at the end of the DCCT, the first quartile showed 
improvements in all profiles related to cardiovascular disease risk; the fourth was associated 
with the negative profiles related to the increasing risk of cardiovascular diseases such as 
higher blood pressures, higher triglyceride (0.99 mmol/l vs 0.79 mmol/l), higher total 
cholesterol (4.97 mmol/l vs 4.55 mmol/l), higher low-density lipoprotein cholesterol (1.32 
mmol/l vs 1.29 mmol/l) and lower high-density lipoprotein cholesterol (3.18 mmol/l 2.82 
mmol/l). Thus improved glycemic control did not seem to result in improvements in the 
cardiovascular risk profiles among patients who gained excessive weight during the insulin 
treatment. Moreover, treatment adherence to prescribed insulin may be compromised by a 
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desire to avoid weight gain [4]. A UK study [23] reported 30% of the women admitted to 
intentionally reducing doses of insulin to control weight gain. Another study [24] in the United 
States also reported that 31% intentionally omitted insulin to avoid weight gain.  
A number of possible mechanisms have been described to explain weight gain on 
insulin therapy including compensation for hypoglycemia [4, 21]. In many patients with 
diabetes, the unpleasant symptoms and negative consequence associated with 
hypoglycemia may result in significant fear of hypoglycemia [17][1]. Because low blood 
glucose levels can be remedied by ingestion of glucose or food, following a hypoglycemic 
event, patients may over-react or be instructed by their physicians to consume more calories 
than necessary (e.g., frequent snacking) in response to the threat of subsequent 
occurrences of hypoglycemia [4, 21].  
Although the hypothesis of compensation for hypoglycemia is well accepted and 
assumed, there is very limited direct evidence to support it in the literature. An early DCCT 
study [25] with a small sample (only the subjects recruited during the first year were used for 
analyses) found that the 29 patients who experienced SH in the intensive therapy group 
gained more weight than the intensively treated subjects with no severe episodes. Another 
study, which re-analyzed data from a 26-week, randomized, open-label trial comparing 
insulin determir with NPH insulin in 476 patients with type 2 diabetes [26], reported no 
correlation between frequencies of hypoglycemia and weight gain for insulin detemir, while a 
correlation was found for NPH insulin(only P values for the correlations were reported in this 
study). However, for these two studies the temporal relation between occurrence of SH or 
hypoglycemia and subsequent weight gain was unclear because some of the weight gain 
may have occurred before the first SH or hypoglycemic episode. Moreover, in the second 
study, the relationship between the frequencies of hypoglycemia and weight gain in this 26-
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week trial was assumed linear in their analyses. However, upon examination of their results, 
the linear assumption is problematic (Figure 2).  
 
 
 
 
Figure 2: Weight Change stratified by Number of Hypoglycemic Events 
from Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin 
detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes 
Technol Ther. 2008; 10(4):273-277. 
 
 
 
      
 
III. STATEMENT OF SPECIFIC AIMS 
We conducted a secondary data analysis using data from the DCCT trial to address 
the following specific aims: 
A. Specific aim 1: 
To estimate the effects of SH (index SH) on subsequent SH in three subsequent time 
windows at months 1-3, 4-6 and 7-9 after index SH in patients with type 1 diabetes. 
Hypothesis 1.1: 
The time window which is closest to the index SH will have the greatest risk/effect of 
SH among the three observation windows.  
Hypothesis 1.2: 
If the hypothesis 1.1 does not hold, compared to those without occurrence of index 
SH the greater risk of subsequent SH episodes will occur immediately after index SH in the 
first observation window at months 1-3. 
B. Specific aim 2: 
Aim 2_1: to estimate the effects of SH (index SH) on subsequent weight 
change/actual weight in various observation periods from 3, 6, 9, 12, 24 and 32 months after 
index SH, respectively;  
 Aim 2_2: to estimate the effects of SH (index SH) on subsequent weight change in 
three fixed-term time windows during the months 1-3, 4-6 and 7-9 after index SH, 
respectively; 
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Aim 2_3: to estimate the effects of occurrence of SH on the time to substantial 
weight gain (defined as the 5, 10, 15 and 20% weight gain from the baseline), becoming 
overweight or obese, respectively in patients with type 1 diabetes.  
Hypothesis 2: 
A short-term weight gain after index SH (e.g., 3-9 months after index SH) will be 
observed but not for a long-term weight gain including substantial weight gain, overweight or 
obesity in the DCCT population. 
C. Specific aim 3: 
To explore whether occurrence of SH is associated with a decrease of insulin dosing 
in the DCCT population. This is a supplementary analysis to provide results to assist 
interpretations of results in aim 1 and 2. 
 
      
 
IV. METHODS 
A. Overview of methods 
We conducted a secondary data analysis using data from the DCCT trial study. The 
DCCT is a randomized clinical trial whose primary aim is to establish the relative 
effectiveness of intensive vs. conventional therapy in term of reducing microvascular and 
macrovascular complications among type 1 diabetes mellitus [27]. 1,441 patients from 29 
clinical centers were randomized to two treatment arms and followed up for a mean of 6.5 
years between 1983 and 1993. 
To address study aim 1, we estimated the relative risk (RR) of SH (index SH) on 
subsequent SH in three subsequent time windows after the index SH based on quarterly 
visits in the DCCT: between the 1st and 2nd, between the 2nd and 3rd, between the 3rd and 4th 
quarterly visit after the index SH, which corresponds to approximate months 1-3, 4-6, and 7-
9 after index SH, respectively (Figure 3). We also estimated transition probabilities as the 
risk of subsequent SH episodes in the three subsequent observation windows using the 
estimation models. We assigned fixed values for the covariates in the estimation models to 
produce predictive values as the corresponding transition probabilities. Since each patient 
could contribute multiple observations, we used generalized estimating equations (GEE) by 
specifying working correlation structure as “exchangeable” to allow for the dependence of 
observations within a person [28, 29]. 
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Figure 3: Study design for estimation of acute effects of severe hypoglycemia (SH) on 
subsequent recurrent episodes in three time windows in the DCCT population 
Effects of SH (index SH) on the risk of subsequent SH were estimated in three subsequent 
time windows (the duration of each time is a quarterly interval) between the 1
st
 and 2
nd 
quarterly visit (corresponding to A in above figure), between the 2
nd
 and 3
rd 
quarterly visit (B 
in above figure), between the 3
rd
 and 4
th
 quarterly visit (C in above figure) after the index SH, 
respectively. These three time windows approximate months 1-3, 4-6, and 7-9 after the index 
SH, respectively. It should be noted that the above defined windows would not be the exact 
durations as the months 1-3, 4-6 and 7-9 after index SH because the period between the time 
when the index SH occurred and the time when the next quarterly visit was conducted would 
not be captured by this definition. However, we use months to describe the timeline after the 
index SH in all sections in this paper for simplicity. Both exposure (index SH) and outcome 
variables (subsequent SH episodes) for three observation windows were defined as 
dichotomized variables. Each patient would contribute multiple observations. To validly 
estimate the effects of index SH, the most recent values of relevant time-dependent 
covariates measured in the time points prior to the index SH were used to control for 
confounding. 
 
4th quarterly 
visit after 
index SH 
3rd quarterly 
visit after 
index SH 
2nd quarterly 
visit after 
index SH 
B Index SH 
Subsequent SH 
Index SH Subsequent SH 
C 
1st quarterly 
visit after 
index SH 
Subsequent SH 
2nd quarterly 
visit after 
index SH 
3rd quarterly 
visit after 
index SH 
Index SH A 
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To address study aim 2_1 and 2_2, we estimated the effects of SH (index SH), which 
occurred in a quarterly interval, on weight change/weight in the following various periods 
(one, two, three, four, eight, and twelve consecutive quarterly intervals), and the effects of 
index SH on weight change in three fixed-term time windows during the 1st, 2nd and 3rd 
quarterly interval. Each patient could contribute multiple observations (Figure 4). The 
different numbers of involved quarterly intervals from one to twelve approximated the 
observation periods with various durations from 3 months to 36 months after index SH, and 
three fixed-term time windows approximated the periods during months 1-3, 4-6 and 7-9 
after index SH, respectively. Similarly, since each patient could contribute multiple 
observations, we used GEE by specifying working correlation structure as “exchangeable” to 
allow for the dependence of observations within a person. 
To address study aim2_3, we used Cox proportional hazard models to estimate the 
hazard ratios (HRs) of SH on the substantial weight gain (defined as the  5, 10, 15 and 20% 
weight gain from the DCCT baseline, respectively), on becoming overweight (BMI≥25.0), or 
on becoming obese (BMI≥30.0) comparing patients after they had their first SH episode with 
all patients who did not experienced any SH episode at the same time during the follow-up 
(they could have a SH episode later during follow-up) [30]. Hence, the exposure in our Cox 
models was treated as a time-dependent variable. Furthermore, as an ancillary analysis, we 
further used marginal structural models (MSM) that allowed us to control for average daily 
insulin dose, which may be seen as a time-dependent confounder affected by prior SH. 
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Figure 4: Diagram for study design to estimate the effects of occurrences of severe 
hypoglycemia (SH) on subsequent weight change/weight during various observation periods 
(only the first, second and third observation period are shown) 
First, the effect of SH which occurred in a quarterly interval on weight change/weight in the 
next quarterly interval (a period approximates a duration of 3-month) was examined (the “A” 
in above figure). Then, we examined the effects of SH on weight during longer periods 
ranging from two (the “B” above included the first two consecutive quarterly intervals after 
SH), three (the “C” included the first three consecutive quarterly intervals after SH), four, 
eight and twelve consecutive quarterly intervals after SH.  The different numbers of quarterly 
intervals approximate observation durations ranging from 3 months to 36 months after SH. 
We defined all time-dependent covariates using the most recent value before the occurrence 
of SH. 
Two continuous outcome variables were defined for each observation period: 1) the first 
outcome variable (weight change) was the difference between the weight measured at the end 
of observation period and the weight at the beginning of the observation period; 2) the 
second was the actual weight measured at the end of observation period.  
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Daily changes of therapy regimens in the DCCT were not centrally documented and 
were not accessible for analysis, and only typical daily insulin doses (TDID) for the past 
quarterly interval were recorded at quarterly visits [31]. Thus, in the DCCT there is no way to 
tell whether the reported dose actually reflected the dose before occurrence of SH or after 
occurrence of SH if patients had occurred SH episodes in a quarterly interval. To account for 
this issue and conduct the supplementary analysis for study aim 3, new study analytic units 
were constructed and each analytic unit consisted of two consecutive quarterly visits to 
account for temporality of change of insulin dose following occurrence of SH (Figure 5). We 
estimated the effects of SH occurring in the first composed quarterly interval in an analytic 
unit on the continuous outcome (the difference of daily insulin doses between the end and 
beginning of the analytic unit) and the dichotomized outcome (≥ 10% dose reduction) in 
each analytic unit. We also used GEE to account for multiple-observations per patient and to 
control relevant factors. Furthermore, for continuous outcome (the difference of daily insulin 
doses), we also used mixed models as a sensitivity analysis. 
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Figure 5: Diagram for Construction of an Analytic Unit for Occurrence of Severe 
Hypoglycemia (SH) on Changes of Typical Daily Insulin Dose (TDID) in the DCCT 
The defined analytic unit consists of two consecutive quarterly intervals (quarterly intervals 
K and K+1 in above figure). In order to be eligible as such an analytic unit, SH must not 
occur in the quarterly interval (interval K-1) preceding the defined unit. Exposure status 
(yes/no) in each defined study unit depends on the occurrence of SH in the first composed 
quarterly interval (interval K). Both continuous variable (the differences of TDID between 
the end and beginning of unit) and dichotomized variable (≥ 10% TDID reduction) were used 
as the outcome for analytic unit. Only intervals after the 1
st
 year follow-up were included in 
the analysis to account for probable bias due to the transition period when patients entered 
the trial.    
 
B. Methods for proposed aims 
1. Data source 
a. The DCCT study 
The DCCT is a randomized controlled clinical trial starting in 1983. 1,441 people with 
type 1 diabetes in the USA and Canada were randomly assigned to receive either intensive 
Difference of the TDIDs 
between the end and 
beginning of the analytic units 
Occurrence of SH in the 
first composed quarterly 
interval in analytic unit as 
Quarterly interval K Quarterly interval Quarterly interval K -
One study analytic unit 
No SH occurred in the 
quarterly interval prior 
to the analytic unit. 
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therapy (three or more insulin injections or continuous subcutaneous insulin infusion) or 
conventional therapy (one or two insulin injection per day). Intensive therapy aimed to keep 
hemoglobin A1C as close to normal (6 %) as possible. After an average follow-up of 6.5 
years, the intensive therapy group achieved a median HbA1c with 7.3% vs. 9.1% for the 
conventional therapy. The trial also showed that intensive treatment aimed at maintaining 
near-normal blood glucose values markedly reduced the risk of microvascular complications 
including retinopathy, nephropathy, and neuropathy [32] .  
At the end of the DCCT, the occurrence of SH was three times higher in the intensive 
than in the conventional therapy group. Almost half the DCCT overall cohort had one or 
more episodes of SH. Of these, 71% had multiple events. For 10 or more episodes, the 
respective percentages were 14.2% of the intensive group and 2.5% of the conventional 
group [18]. By the end of the study, 42% of the intensively treated patients had exceeded 
the overweight limits at some point during follow-up as compared to 27% of the 
conventionally treated patients, and the pattern was uniform among men, women, adults, 
and adolescents [18].  
During the trial, intensive therapy had specific glucose targets: 70-120 mg/dl before 
meals, <180 mg/dl after meals, and >65 mg/dl at 3 am. Intensive therapy group subjects 
could choose a regimen consisting of either multiple daily injections or continuous 
subcutaneous insulin infusion with an external pump, both guided by the frequent self-
monitoring of blood glucose levels. All aspects of the intensive therapy regimen were subject 
to change as needed to reduce the risk of hypoglycemia when indicated. Subjects in the 
conventional therapy group used one or two insulin injections per day and monitored either 
urine or blood glucose without specific numeric glucose targets. The daily changes of 
therapy regimens were not centrally documented and were not accessible for analysis. 
However, during the average 6.5 years follow-up in the DCCT, every participant had 
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quarterly visits. At the quarterly visit, the typical daily insulin doses for the past interval were 
recorded and the capillary blood hemolysates for a daily blood glucose profile were collected 
at the day before quarterly visit at seven points throughout the day, namely pre-breakfast, 
post-breakfast, pre-lunch, post-lunch, pre-supper, and post-supper and bedtime. For these 
seven-point blood samples, capillary blood hemolysates were collected before meals, 90 
min after meals and at bedtime by patients in the home the day before the quarterly visit. 
Blood glucose was measured in a central laboratory using a hexokinase enzymatic method. 
Subjects were instructed to report all episodes of suspected severe hypoglycemia (requiring 
assistance of others to manage hypoglycemia) immediately; all were interviewed regarding 
the episodes. In addition, subjects were also asked at the quarterly visits about the 
occurrence of any hypoglycemia [27, 31]. 
Patients in the intensive therapy group were seen at least monthly and telephone 
contact was as often daily for the first few weeks, then weekly thereafter. Their A1C results 
were unmasked by investigators. The patients on the intensive therapy also were instructed 
to perform self-blood glucose monitoring at least four times a day and also were instructed 
to conduct a further test a 3:00 A.M. if their glucose value was less than 65mg/dl. On the 
contrary, the patients on the conventional therapy were seen only quarterly and they did not 
have any specific glucose control targets. Their A1C values often were masked by 
investigators during the follow-up. The patients on the conventional therapy were not asked 
to take self-blood glucose monitoring early in the trial. Later with the increased use of self-
blood glucose monitoring in clinical practice, this technique was made part of the 
conventional therapy in 1986. But they were only asked to perform at least one self-blood 
glucose monitoring or one urine test per day [31]. 
In the trial, registered dietitians tailored meal plans and educational strategies to the 
need and life style of each individual to achieve and maintain ideal body weight with goals of 
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15-20% of energy from protein, 30-35% from fat, and 50-55% from carbohydrate. Patients in 
the intensive therapy received more frequent and detailed instruction on individualized meal 
plans. Since weight gain with intensive therapy had been recognized, dietitians increased 
their emphasis and counseling on weight management for patients in the intensive therapy, 
and greater attention was given to the relation between nutrient intake and insulin to try to 
achieve target glycemic levels without hypoglycemia or weight gain [31]. 
The DCCT data is publicly accessible through the National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) central repository 
(https://www.niddkrepository.org/niddk/home.do).  
b. Study populations 
For study aim 1, to allow for learning during the transition period when patients 
entered the trial, we only included quarterly visits after the first year of follow-up in the DCCT 
as analytic intervals in our analysis. We also restricted eligible patients who must be 18 
years or older when they entered the DCCT trial, since younger patients were treated 
differently for glycemic control and would differ in term of self-management of type 1 
diabetes from adult patients [31]. 
For study aim 2, we restricted eligible patients to be 18 years or older when they 
entered the DCCT to avoid weight gain as a result of adolescent growth. In addition, we also 
censored female patients at the time of their first pregnancy during follow-up based on their 
reported last menstrual dates.  
For study aim 3, we also only included quarterly visits after the first year of follow-up 
in the DCCT to define the analytic units, and restricted eligible patients who must be 18 
years or older when they entered the DCCT trial and censored female patients at the time of 
their first pregnancy during follow-up based on their reported last menstrual dates. 
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2. Measures of exposure 
SH was defined as an episode in which a patient required assistance of another 
person and the following conditions: 1) a blood glucose level of < 50 mg/dl, or 2) prompt 
recovery following oral carbohydrate, intravenous glucose, or glucagons. Patients in the 
DCCT were instructed to report all episodes of suspected SH immediately, and all were 
interviewed to verify each episode [31]. 
For study aim 1, the exposure was a dichotomized variable to indicate the 
occurrence of SH in an eligible study quarterly interval. 
For study aim 2_1 and 2_2, similarly, the exposure was a dichotomized variable to 
indicate the occurrence of SH in an eligible study quarterly interval.  For study aim 2_3, 
although the exposure was still to indicate the occurrence of SH, it was a variable based on 
the occurrence of the first SH episode during the follow-up: 1) the patient was defined as 
unexposed prior to the 1st SH episode in their follow-up in the DCCT; 2) after the 1st SH 
episode, the patient was defined as always exposed.  
For study aim 3, the exposure was a dichotomized variable to indicate the 
occurrence of SH in the first composed quarterly interval in each defined analytic unit. 
3. Measures of outcome 
For study aim 1, the dichotomized outcome was the subsequent occurrence of SH 
(the same definition as the exposure for SH above) in three observation windows after index 
SH (exposure). 
  For study aim 2_1, two continuous outcome variables were defined for each 
observation period with ranges from 3 to 36 months after index SH: 1) the first outcome 
variable (weight change) was the difference between the weight measured at the end of 
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observation period and the weight at the beginning of the observation period; 2) the second 
was the actual weight measured at the end of observation period.  For study aim 2_2, the 
outcome was the quarterly weight change for three fixed-term time windows, respectively. In 
the DCCT, weight (in kilograms) was measured with patients in light clothing and stockings 
on the same balance-beam scale for the duration of the DCCT trial [27]. 
For study aim 2_3, the outcome substantial weight gain was defined as the time to 5, 
10, 15 and 20% weight gain from the DCCT baseline, respectively at the first time during the 
follow-up. We also looked at the time to overweight (BMI values ≥25.0), and time to obesity 
(BMI values ≥30.0), respectively at the first time as outcomes [33].   
For study aim 3, two types of outcome were defined in each analytic unit: 1) 
continuous variable (the differences of insulin doses between the end and beginning of 
analytic unit); 2) dichotomized variable (≥ 10% insulin reduction).  
4. Covariate measurement 
Relevant covariate information was obtained from the baseline and quarterly visit 
data files in the DCCT. Table 2-4 showed that the relevant covariates with their definitions 
and formats were used in final statistical models for each specific aim. 
For continuous covariates, besides using their original values, power terms or 
categories, we also explored to use spline terms in estimation models for better confounding 
control.  Spline models could combine the advantages of categorical and power models [34].  
We categorized continuous covariate or created the knots for their splines based on 
established cut-points (e.g., BMI) or known conventions. Otherwise, we used empirical cut-
points based on the actual distributions from data themselves (e.g., the different distribution 
percentiles). When to estimate the parameters for the main exposure, we tried several 
parameter specifications (original values, categories and splines) for continuous covariates 
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in the models and various specifications appeared to yield a similar result in term of the 
estimates for the main exposure. Based on the precision of the estimates for the main 
exposure and model fit statistics: quasilikelihood under the independence model criterion 
(QIC) for GEE and Akaike information criterion (AIC) for Cox models [35], the most 
appropriate specifications (formats) for continuous covariates were used in final models for 
different specific aims.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Table 2 : Covariates adjusted in the models for study aim 1 
Variable Formats Notes 
Gender 2 categories (female, male) Measure at the DCCT baseline 
Age 
3 categories “18-25, 26-29, and >29 years 
of old ” Measure at the DCCT baseline 
Duration of type 1 
diabetes 3 categories “1-5, 6-10 and >10 years” Measure at the DCCT baseline 
History of SH 2 categories (Yes/No) Based on the DCCT baseline file 
Recent SH 
Dichotomized variable to indicate the 
occurrence in the quarterly interval prior to 
index SH (exposure) Updated quarterly 
Rates of SH 
episodes from 
baseline to prior to 
the index SH 
3 categories “no occurrence  prior to the 
index SH, less or equal to the 90
th
 
percentiles of the rates in corresponding 
treatment groups, and greater than 90
th
 
percentiles” Updated quarterly 
Expected A1C 
4 categories “<6%, 6-6.9%, 7-7.9% and 
≥8%” 
Calculated from mean blood 
glucose with quarterly blood 
glucose profiles based on 
previous studies [36, 37], 
updated quarterly 
Actual A1C 
4 categories “<6%, 6-6.9%, 7-7.9% and 
≥8%” Updated quarterly 
Alcohol use 
3 categories “no use, 1-75 grams per 
week, >75 grams per week” Updated annually 
Physical activities 
3 categories “little, moderate and 
strenuous” Updated annually 
Meal plan 
adherence 
Dichotomized variable for whether subjects 
claimed to have followed the meal plan 
almost all of the time in quarterly 
questionnaire Updated quarterly 
Insulin use 
adherence 
Dichotomized variable for whether subjects 
claimed to have followed the prescribed 
insulin dose in quarterly questionnaire Updated quarterly 
Use of SMBG 
3 categories “no use, often done and at 
least one per day” Updated quarterly 
Blood glucose 
variability 
Standard deviation calculated from 
quarterly blood glucose profiles for 
individual subjects Updated quarterly 
Follow-up time  
A restricted cubic spline with 5 knots at 5, 
10, 25, 75 an 95
th
 percentiles of the months 
since entered the DCCT Updated quarterly 
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Table 3: Covariates adjusted in the models for study aim 2_1 and 2_2 
Variable Formats Notes 
Gender 2 categories (female, male) 
Measure at the 
DCCT baseline 
Age 3 categories “18-25, 26-29, and >29 years of old ” 
Measure at the 
DCCT baseline 
Duration of type 1 
diabetes 3 categories “1-5, 6-10 and >10 years” 
Measure at the 
DCCT baseline 
History of SH 2 categories (Yes/No) 
Based on the 
DCCT baseline 
file 
Recent SH 
Dichotomized variable to indicate the occurrence in the 
quarterly interval prior to index SH (exposure) 
Updated 
quarterly 
Rates of SH episodes 
from baseline to prior to 
the index SH 
3 categories “no occurrence prior to the index SH, less 
or equal to the 90
th
 percentiles of the rates in 
corresponding treatment groups, and greater than 90
th
 
percentiles” 
Updated 
quarterly 
Physical activity 3 categories “little, moderate and strenuous” 
Updated 
annually 
Meal plan adherence 
Dichotomized variable for whether subjects claimed to 
have followed the meal plan almost all of the time in 
quarterly questionnaire 
Updated 
quarterly 
Insulin adherence 
Dichotomized variable for whether subjects claimed to 
have followed the prescribed insulin dose in quarterly 
questionnaire 
Updated 
quarterly 
BMI prior to SH 
a restricted quadratic spline with 3 knots at BMI 18.5, 
24.9 and 29.9 
Updated 
quarterly 
Quarterly daily insulin 
dose 
a restricted quadratic spline with 3 knots at 5
th
 , 50
th
  and 
95
th
 percentiles 
Updated 
quarterly 
Follow-up time  
A restricted cubic spline with 5 knots at 5, 10, 25, 75 an 
95
th
 percentiles of the months since entered the DCCT 
Updated 
quarterly 
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Table 4: Covariates adjusted in the models for study aim 2_3 
Variable Formats Notes 
Gender 2 categories (female, male) 
Measure at the 
DCCT baseline 
Age 
a restricted quadratic spline with 3 knots at 5
th
, 50
th
  and 
95
th
 percentiles 
Measure at the 
DCCT baseline 
Duration of type 1 
diabetes 
a restricted quadratic spline with 3 knots at 5
th
 , 50
th
  and 
95
th
 percentiles 
Measure at the 
DCCT baseline 
History of SH 2 categories (Yes/No) 
Based on the DCCT 
baseline file 
BMI Continuous variable 
Measured at the 
DCCT baseline 
Average physical 
activities 
Dichotomized variable on whether a subject had 
strenuous activities in 80% of follow-up time or more. Updated annually 
Average meal plan 
adherence 
Dichotomized variable on whether a subject had claimed 
to follow meal plan in 80% of follow-up time or more. Updated quarterly 
Average daily 
insulin dose 
A restricted quadratic spline with 3 knots at 5
th
 , 50
th
  and 
95
th
 percentiles Updated quarterly 
 
5. Statistical analyses 
a. Estimation of the acute effects of SH on subsequent SH 
We estimated the RRs of SH (index SH) on subsequent SH in three subsequent time 
windows after the index SH corresponding to approximate months 1-3, 4-6, and 7-9 after 
index SH, respectively. It should be noted that the above defined windows would not be the 
exact durations as the months 1-3, 4-6 and 7-9 after the index SH because the period 
between the time when the index SH occurred and the time when next quarterly visit was 
conducted would not be captured by this definition (Figure 3). However, we used months to 
describe the timeline after index SH in the following sections for simplicity.  
We used log-linear multivariable models to estimate RRs and their 95% confidence 
intervals (CI). We controlled for confounding by a set of priori specified covariates (Table 2) 
based on directed acyclic graph (DAG) [38] (Figure 6).  We defined all time-dependent 
covariates using the most recent value before the occurrence of the index SH to avoid the 
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value to be in the intermediate pathway between the exposure and outcome. Since each 
patient could contribute multiple observations, we used GEE by specifying working 
correlation structure as “exchangeable” to allow for the dependence of observations within a 
person [28, 29]. When the log-linear models did not converge, we used Poisson models to 
approximate RRs as previously described [39].  
We also estimated transition probabilities as the risk of subsequent SH episodes in 
the three subsequent observation windows using the estimation models. We assigned the 
following values for the covariates in the estimation models including the intercept term and 
to produce predictive values as the corresponding transition probabilities (except for the 
index SH, we fixed all covariates with the following referent values in corresponding models): 
occurrence of index SH (yes or no), gender (female), baseline age (>29 years), duration of 
disease ( >10 years) and history of SH (no), most recent SH (no) and incidence rates of SH 
episodes (less or equal to the 90th percentiles of the rates in corresponding treatment groups 
up to the index SH), expected A1C (6-6.9%), actual A1C (6-6.9%), alcohol use (no use), 
exercise activities (moderate), meal plan (adherence) and insulin adherence (adherence), 
use of SMBG (often done), blood glucose variability (population mean 3.89) and the follow-
up time (24 months). I did not include any occurrences of SH in three subsequent time 
windows following index SH as the covariates in the models to obtain transition probabilities. 
For instance, we did not include occurrences of SH in the first 3-month observation window 
as the covariates in the models when estimating the transition probabilities for subsequent 
SH episodes in the 4-6 and 7-9 month observation windows after the index SH because the 
occurrences of SH in the first 3-month were treated as the intermediated effects of the index 
SH on the 4-6 and 7-9 month observation windows. If log-linear models could not converge, 
we used logistic regression to estimate transition probabilities.  
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Figure 6: Directed acyclic graph for the effect of occurrence of SH (index SH) on subsequent 
SH episodes in observation windows following index SH. 
 
 
b. Estimation of the effects of SH on subsequent weight gain over various periods 
We used linear multivariable models to estimate the effects of SH (index SH), which 
occurred in a quarterly interval, on weight change/actual weight in various periods with 
Index SH (exposure) Subsequent SH (outcome)
Gender
Age at DCCT baseline
Duration of type 1 diabetes at DCCT baseline
blood glucose variability prior to index SH
Use of SMBG  prior to index SH
insulin use adherence prior to index SH 
meal plan adherence prior to index SH  
physical activities prior to index SH  
alcohol use  prior to index SH
actual A1C prior to index SH  
expected A1C prior to index SH  
Recent SH prior to index SH
Rates of SH prior to index SH
History of SH at DCCT baseline
Follow-up time
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ranges approximately from 3 months to 36 months after index SH. We also looked at the 
effects of index SH on weight change in three subsequent fixed-term time windows at the 1st, 
2nd and 3rd quarterly interval following index SH (the observation period for each time 
window approximated a 3-month period in this analysis), and the outcome as the weight 
change in this analysis was the quarterly weight change for three fixed-term time windows, 
respectively. The corresponding comparison intervals were the intervals without occurrence 
of index SH.  
We controlled for confounding by including a set of priori specified covariates in the 
models based on DAG (Figure 7). We tried several parameter specifications (original values, 
categories and splines) for continuous covariates in the models. Based on the precision of 
the estimates for the main exposure and model fit statistics, the most appropriate 
specifications (formats) for continuous covariates were used in final models (Table 3). Since 
each patient could contribute multiple observations, similarly we used GEE by specifying 
working correlation structure as “exchangeable” to allow for the dependence of observations 
within a person [28, 29].  
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Figure 7: Directed acyclic graph for the effect of occurrence of SH (index SH) on 
subsequent weight change/weight in various periods following index SH. 
 
c. Estimation of the effects of SH on substantial weight gain, overweight, and obesity 
We used Cox proportional hazard models to estimate the HRs of SH on the 
substantial weight gain (defined as the 5, 10, 15 and 20% weight gain from the DCCT 
baseline, respectively), on becoming overweight (BMI≥25.0), or on becoming obese 
(BMI≥30.0) comparing patients after they had their first SH episode with all patients who did 
Index SH (exposure) Subsequent weight change/weight (outcome)
Gender
Age at DCCT baseline
Duration of type 1 diabetes at DCCT baseline
Daily insulin dose  prior to index SH
insulin use adherence prior to index SH 
meal plan adherence prior to index SH  
physical activities prior to index SH  
BMI prior to index SH  
Recent SH prior to index SH
Rates of SH prior to index SH
History of SH at DCCT baseline
Follow-up time
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not experienced any SH episode at the same time during follow-up (they could have a SH 
episode later during follow-up) [30]. Hence, the exposure in the Cox models was a time-
dependent variable: 1) the patient was defined as unexposed prior to the 1st SH episode; 2) 
after the 1st SH episode, the patient was defined as always exposed. We checked the 
proportional hazards assumption for main exposure by adding an interaction term between 
the exposure and the follow-up time. We controlled for confounding by including a set of 
priori specified covariates (Table 4) in the models based on the DAG (Figure 8). 
 
 
Figure 8: Directed acyclic graph for the effect of occurrence of SH on developing 
substantial weight gain, overweight or obesity during the follow-up. 
 
Occurrence of SH (exposure) Substantial weight gain/overweight/obesity (outcome)
Gender
Age at DCCT baseline
Duration of type 1 diabetes at DCCT baseline
Average meal plan adherence  
Average physical activities  
Average daily insulin dose
History of SH at DCCT baseline
BMI at DCCT baseline
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Average daily insulin dose may be seen as a time-dependent confounder affected by 
prior SH (Figure 9). Under this assumption the Cox model controlling for average daily 
insulin dose as well as a model not controlling for it would be biased [40]. Furthermore, as 
an ancillary analysis, we therefore used marginal structural models (MSM) that allow us to 
control for average daily insulin dose that may be affected by exposure. I used weighted 
pooled logistic regression models to approximate the parameters of the MSM [13].  Fitting 
the weighted estimation of the parameters involved three sets of models: 1) a pooled logistic 
model estimating the time-varying exposure propensity (the probabilities to have the first SH 
episode during the follow-up), 2) a pooled logistic model estimating the probability of 
censoring, and 3) the final model weighting exposed and unexposed by the weights 
obtained in steps 1) and 2) to obtain the estimates for the main exposure with robust 
standard errors for the confidence intervals. We used a restricted spline with 3 knots for all 
continuous variables in all sets of models as recommended [41]. To estimate the time-
dependent intercept for all three models in the MSM, we produced a restricted cubic spline 
for the follow-up time (the numbers of months since start of the trial) with SAS macro 
RCSPLNE [42]. We also examined the distribution of the estimated weights to check 
whether the weights were well constructed (the well-constructed weights should have a 
mean around 1 and narrow ranges for the estimated weights) [41]. 
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Figure 9: Conceptual directed acyclic graph to show that covariate average daily 
insulin dose may be an intermediate and time-dependent confounder for the 
association between the occurrence of severe hypoglycemia (exposure) and time to 
substantial weight gain, time to becoming overweight or time to becoming obese 
during follow-up. 
 
d. Estimation of the effects of SH on insulin dosing changes 
As a supplementary analysis, we used linear multivariable models to estimate the 
effects of SH occurring in the first composed quarterly interval in an analytic unit on the 
continuous outcome (the difference of daily insulin doses between the end and beginning of 
the analytic unit) and used log-linear multivariable models on the dichotomized outcome (≥ 
10% dose reduction) in each analytic unit. Each analytic unit consisted of two consecutive 
quarterly visits to account for temporality of change of insulin dose following occurrence of 
SH (Figure 5). We used generalized GEE to account for multiple-observations per patient 
and to control relevant factors with working correlation structure “exchangeable”. 
Furthermore, for continuous outcome (the difference of daily insulin doses), we also used 
mixed models as a sensitivity analysis. However, negative variance components were 
Substantial weight gain
/overweight/obesity (outcome)
Exposure status 
at time K
Exposure status 
at time K+1
Average insulin dose 
up to time K
Average insulin 
dose up to time K+1
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reported when we used a random effect for the intercept for each subject by covariance 
structure as either variance component or unstructured in the mixed models. After serial 
diagnostic tests, we omitted the random effect for the intercept, but correlation within the 
random effect was modeled by including covariance parameter in the residual variance 
matrix R with a toeplitz structure and toep (5) appeared a best fit.  
 
 
 
 
      
 
V. RESULTS 
A. Estimation of acute effects of severe hypoglycemia on subsequent episodes in 
type 1 diabetes 
1. Introduction 
Hypoglycemia is the predominant limiting factor in the glycemic management of type 
1 diabetes [2]. Severe hypoglycemia (SH), which requires the assistance of another person 
and cannot be treated by patients themselves, can further induce hypoglycemia-associated 
autonomic failure, a defect in counterregulation and loss of awareness of hypoglycemia [8]. 
Thus, SH can cause a vicious cycle of recurrent hypoglycemia, and the effect of SH on 
subsequent episodes is often inferred as an acute effect with the greatest risk occurring in 
weeks and months immediately following SH [1, 8].  
Although prior studies have consistently reported SH as a general risk factor for 
recurrent SH episodes [9, 10, 16], very few studies provide epidemiologic evidence to 
demonstrate the acute effects of SH on subsequent SH in a clinically relevant time range, 
and the magnitude of such effects from population levels in patients with type 1 diabetes is 
not completely clear. One Scottish study with 94 subjects with type 1 diabetes reported that 
the occurrence of hypoglycemia in the previous month was associated with the occurrence 
of hypoglycemia in next month, with an odds ratio of 4.6 (CI: 1.5-13.7) [15]. The effect 
appears greater in this study compared to estimates reported by other studies that did not 
restrict their definition of exposure and outcome to a short time range [9, 10, 16], and the 
results of this study seem to support the notion of an acute effect [1]. However, this study 
followed participants for only one month and had a very small sample size.  
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The objectives of this study are to estimate and illustrate the acute effects of SH on 
risk of subsequent SH episodes in patients with type 1 diabetes.  
2. Methods 
Study population 
We used data from the Diabetes Control and Complications Trial (DCCT), which 
randomized 1,441 patients between ages of 13 to 39 with duration of type 1 diabetes 1-15 
years to either intensive therapy or conventional therapy between 1983 and 1993. Patients 
were followed through quarterly clinic visits [31]. The trial was designed to compare 
intensive and conventional therapies and their relative effects on the development and 
progression of diabetic complications. Patients on intensive therapy had specific glucose 
targets (to keep A1C as close to 6% as possible with daily targets at 70-120 mg/dl before 
meals, <180 mg/dl after meals, and >65 mg/dl at 3 am) and could choose a regimen 
consisting of either multiple daily injections or continuous subcutaneous insulin infusion with 
an external pump. They also were required to conduct frequent self-monitoring of blood 
glucose (SMBG), were seen by their health care team monthly, and were contacted by 
telephone weekly. Patients randomized to the conventional therapy only saw the team 
quarterly, used one or two insulin injections per day, and monitored either urine or SMBG 
without specific glucose targets [31]. 
To allow for learning during the transition period when patients entered the trial, we 
only included quarterly visits after the first year of follow-up as analytic intervals in our 
analysis. We also restricted eligible patients who must be 18 years or older when they 
entered the trial, since younger patients were treated differently for glycemic control and 
would differ in term of self-management of type 1 diabetes from adult patients [31]. 
Definition of SH 
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SH was defined as an episode in which a patient required assistance of another 
person and the following conditions: 1) a blood glucose level of < 50 mg/dl (if available), or 2) 
prompt recovery following oral carbohydrate, intravenous glucose, or glucagons. Patients in 
the DCCT were instructed to report all episodes of suspected SH immediately, and all were 
interviewed to verify each episode [31]. 
Estimation of the acute effects of SH on subsequent SH 
We estimated the relative risk (RR) of SH (index SH) on subsequent SH in three 
subsequent time windows after the index SH based on quarterly visits in the DCCT: 
between the 1st and 2nd, between the 2nd and 3rd, between the 3rd and 4th quarterly visit after 
the index SH, which corresponds to approximate months 1-3, 4-6, and 7-9 after index SH, 
respectively (Figure 3). It should be noted that the above defined windows would not be the 
exact durations as the months 1-3, 4-6 and 7-9 after the index SH because the period 
between the time when the index SH occurred and the time when next quarterly visit was 
conducted would not be captured by this definition. However, we use months to describe the 
timeline after index SH in the following sections for simplicity.  
We used log-linear multivariable models to estimate relative risks and their 95% 
confidence intervals (CI). We controlled for confounding by the following a set of priori 
specified covariates based on directed acyclic graph [38](Figure 6): 1) time-independent 
variables: gender, baseline age (3 categories “18-25, 26-29, and >29 years of old ”), 
duration of disease (3 categories “1-5, 6-10 and >10 years”) and history of SH (dichotomized 
variable based on the interview as the same definition above) at the DCCT baseline; 2) 
time-dependent variables: recent SH (dichotomized variable to indicate the occurrence in 
the quarterly interval prior to index SH) and rates of SH episodes prior to the index SH (3 
categories “no occurrence prior to the index SH, less or equal to the 90th percentile of the 
rates in corresponding treatment groups, and greater than 90th percentile”), expected A1C (4 
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categories “<6%, 6-6.9%, 7-7.9% and ≥8%”) calculated from mean blood glucose with 
quarterly blood glucose profiles as previously described [36, 37]), actual A1C (4 categories 
“<6%, 6-6.9%, 7-7.9% and ≥8%”), alcohol use (3 categories “no use, 1-75 grams per 
week, >75 grams per week”), physical activities (3 categories “little, moderate and strenuous” 
based on annual questionnaire), meal plan adherence (dichotomized variable for whether 
subjects claimed to have followed the meal plan almost all of the time in quarterly 
questionnaire) and insulin use adherence (dichotomized variable for whether subjects 
claimed to have followed the prescribed insulin dose in quarterly questionnaire), use of 
SMBG (3 categories “no use, often done and at least one per day”), blood glucose variability 
(standard deviation calculated from quarterly blood glucose profiles for individual subjects) 
and the follow-up time since entry of the DCCT (a restricted cubic spline with 5 knots at 5, 
10, 25, 75 and 95th percentiles of the months since entered the DCCT). We defined all time-
dependent covariates using the most recent value before the occurrence of the index SH. 
Since each patient could contribute multiple observations, we used generalized estimating 
equations (GEE) by specifying working correlation structure as “exchangeable” to allow for 
the dependence of observations within a person [28, 29]. When the log-linear models did not 
converge, we used Poisson models to approximate RRs as previously described [39].  
We also produced transition probabilities as the risk of subsequent SH episodes in 
the same three subsequent observation windows using the above estimation models. We 
assigned the following values for the covariates in the estimation models including the 
intercept term to produce predictive values as the corresponding transition probabilities 
(except for the index SH, we fixed all covariates with the following referent values in 
corresponding models): occurrence of index SH (yes or no), gender (female), baseline age 
(>29 years), duration of disease ( >10 years) and history of SH (no), most recent SH (no) 
and incidence rates of SH episodes (less or equal to the 90th percentile of the rates in 
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corresponding treatment groups up to the index SH), expected A1C (6-6.9%), actual A1C 
(6-6.9%), alcohol use (no use), physical activities (moderate), meal plan (adherence) and 
insulin adherence (adherence), use of SMBG (often done), blood glucose variability 
(population mean 3.89) and the follow-up time (24 months). We did not include any 
occurrence of SH in three subsequent time windows following index SH as the covariates in 
the models to obtain transition probabilities. For instance, we did not include occurrence of 
SH in the first 3-month observation window as the covariates in the models when estimating 
the transition probabilities for subsequent SH episodes in the 4-6 and 7-9 month observation 
windows after the index SH because the occurrence of SH in the first 3-month were treated 
as the intermediated effects of the index SH on the 4-6 and 7-9 month observation windows. 
If log-linear models could not converge, we used logistic regression to estimate transition 
probabilities. All analyses were performed with SAS, version 9.2 (SAS Inc., Cary, NC). 
3. Results 
We identified 1,220 eligible patients who contributed 22,207quarterly visits (intervals) 
from both treatment groups (605 patients in the intensive therapy and 615 in the 
conventional therapy) in the DCCT for our final analysis. The intervals that had prior SH 
events appeared to have lower expected and observed A1C levels in both treatment groups, 
and more intervals in the intensive therapy group were found to have lower expected and 
observed A1C levels than those in the conventional therapy group (Table V-A 1).  
The highest absolute risks (transition probabilities) for subsequent SH episodes after 
index SH were found in the first 3-month observation window in both treatment groups 
(Table V-A 2): in the conventional therapy, the risks to develop subsequent SH episodes in 
the first 3 months, months 4-6 and months 7-9 after index SH were 19.8%, 15.4% and 
15.9%, respectively; the corresponding risks were 21.5%, 21.4% and 17.3% in the intensive 
therapy group.  
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In both treatment groups, the greatest adjusted RRs on the risk of subsequent SH 
episodes were also observed in the first 3 months after the index SH compared to those 
without occurrence of the index SH (Table V-A 3): in the conventional therapy group, the 
RRs (95% CI) in the first 3 months, months 4-6 and 7-9 were 3.38 (2.21, 5.18), 1.37 (0.76, 
2.47) and 1.95 (1.33, 2.87) respectively, and the corresponding RRs were 1.7(1.48, 1.97), 
1.45 (1.2, 1.74) and 1.36 (1.16, 1.61) in the intensive therapy group.   
Similar to RRs, the greatest risk differences (RDs) for the effects of index SH on 
subsequent episodes (calculated by transition probabilities) were also observed in the 1st 
observation window after the index SH in both treatment groups (Table V-A 2).         
4. Discussion 
We observed that the greatest risk of recurrent SH occurred in the follow-up time 
windows closest to recent SH in a population with type 1 diabetes. The results in our study 
support the notion of acute effects of SH on subsequent episodes in patients with type 1 
diabetes on insulin therapy. In addition, our results based on a relatively large population are 
also compatible with a hypothesized underlying biologic mechanism: the recent antecedent 
hypoglycemia may cause defective glucose counterregulation and hypoglycemic 
unawareness, and, therefore, recent SH episodes can lead to more recurrent events, a 
vicious continuing cycle [8]. Hence, besides previous evidence to treat history of SH as a 
general risk factor [43], our study adds further detail for the evidence to indicate that the 
immediate periods after occurrence of SH are crucial to prevent subsequent SH in clinical 
management of type 1 diabetes. 
Our study is not without its limitations with regard to available information to better 
address our research questions and generalization of our findings. First, the daily changes 
of therapy regimens in the DCCT were not centrally documented and were not accessible 
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for analysis. We only had quarterly data available for patients in our study and assumed that 
it was representative of the full quarter for individual patients. Hence, we only can estimate 
the total effects of SH on subsequent SH episodes, and cannot disentangle underlying 
intermediate effects due to physicians and patients’ activities in responding the SH events 
(index SH) on subsequent SH episodes. Our observation that the greatest risk of recurrent 
SH occurred in the follow-up time windows closest to recent SH may only reflect a lag for 
physicians and patients to response the prior SH events (index SH). However, regardless of 
whatever explanations the greater risk on subsequent SH episodes in the first 3-month after 
index SH compared to those without occurrence of index SH suggests that the effect of 
recent SH occur immediately. If the lag to response the index SH can completely explain 
what we observed in this study our results would further demonstrate that a prompt and 
timely response after recent SH is crucial to prevent subsequent SH. Secondly, information 
on activities that affect the risk for SH, including physical activity and alcohol consumption, 
was not available quarterly, and we had to use annual collected information on physical 
activity and alcohol consumption as a surrogate for data for each quarterly visit. However, 
conventional risk factors for SH, including physical activity and alcohol consumption, were 
reported to be well under control in the DCCT because a careful review for these factors 
was performed for the patient once SH occurred in a patient during the trial [10]. Lastly, we 
should be cautious about extrapolating our findings to all patients with type 1 diabetes 
because of the selected trial population and the trial design of the DCCT.  
Notwithstanding these limitations, we were able to utilize longitudinal information 
from the DCCT with 1,220 eligible patients who contributed to 22,207 quarterly intervals to 
illustrate the acute effects of SH over clinically relevant observation periods.  
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In summary, our study adds to the evidence for an acute effect of recent SH on 
subsequent episodes. It indicates that the immediate periods after occurrences of SH are 
crucial in clinical management of type 1 diabetes to prevent subsequent SH. 
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Table V-A 1: Distributions of some covariates by exposure status --occurrence of severe 
hypoglycemia (SH) on risk of subsequent SH in the 1
st
 subsequent observation window in the 
DCCT 
  
Intensive Therapy  
(No. of patients=605) 
Conventional Therapy 
(No. of patients=615) 
  Prior SH No Prior SH Prior SH No Prior SH 
Total contributed  intervals*  1,179 9,920 384 10,724 
Expected A1C levels (%)      
 <6% 26.5 18.2 10.0 4.1 
 6-6.99% 25.2 26.3 13.8 6.8 
 7-7.99% 23.8 23.9 16.1 10.7 
 ≥8% 24.5 31.6 60.1 78.4 
Actual observed A1C (%)      
 <6% 10.2 8.3 6.7 1.4 
 6-6.99% 44.9 40.9 18.4 6.1 
 7-7.99% 35.8 35.9 28.3 16.8 
 ≥8% 9.1 14.8 46.7 75.8 
Self-monitoring of blood 
glucose (%)      
 
at least one per 
day 91.8 93.1 31.9 22.2 
 Often done 7.6 6.0 40.4 50.6 
 No use 0.6 1.0 27.7 27.2 
Alcohol use (%)      
 
more than 75 
grams per week  11.6 10.3 7.3 10.7 
 
1-75 grams  per 
week 23.0 24.4 32.6 27.8 
 No use 65.4 65.3 60.2 61.5 
Physical activities (%)      
 Strenuous 4.6 4.5 9.6 6.1 
 Moderate 56.5 53.2 53.1 52.2 
 Little 38.9 42.4 37.2 41.7 
Meal plan adherence (%)      
 Yes 83.1 81.7 82.8 80.5 
 No 16.9 18.3 17.2 19.5 
Insulin use adherence (%)      
 Yes 75.1 77.3 87.5 87.4 
 No 24.9 22.7 12.5 12.6 
* One patient would contribute multiple observation quarterly intervals. 
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Table V-A 2: Risk (transition probabilities) of severe hypoglycemia (SH) in three subsequent 
observation windows in the DCCT 
Treatment 
Assignment 
Observed window 
after index SH 
No. of 
intervals 
with SH 
episodes 
Total 
contributed 
intervals* 
Transition 
probabilities 
for subsequent 
SH  (TP, %)† 
Differences of 
TP (prior SH 
minus no prior 
SH) 
Intensive 
Therapy Months 1-3     
  Prior SH  350 1,179 21.5 8.9 
  No prior SH 844 9,920 12.6 0.0 (reference) 
 Months 4-6     
  Prior SH  293 1,096 21.4‡ 7.1 
  No prior SH 842 9,398 14.3‡ 0.0 (reference) 
 Months 7-9     
  Prior SH  271 1,038 17.3 4.6 
  No prior SH 792 8,852 12.7 0.0 (reference) 
      
Conventional 
Therapy Months 1-3     
  Prior SH  103 384 19.8 13.9 
  No prior SH 282 10,724 5.9 0.0 (reference) 
 Months 4-6     
  Prior SH  64 358 15.4‡ 4.3 
  No prior SH 301 10,135 11.1‡ 0.0 (reference) 
 Months 7-9     
  Prior SH  64 335 15.9 7.8 
  No prior SH 282 9,543 8.1 0.0 (reference) 
* One patient would contribute multiple observation intervals; 
†Assigned following values for the covariates including the intercept in models to produce transition 
probabilities: intercept (1), occurrence of prior SH (yes or no), gender (female), baseline age (>29), duration of 
disease (> 10) and history of SH (no), most recent SH (no) and incidence rates of SH episodes up to the index 
SH (less or equal to the 90
th
 percentiles of incidence rates in the corresponding treatment groups), expected A1C 
( 6-6.9%), actual A1C (6-6.9%), alcohol use (no use), physical activities (moderate), meal plan (adherence) and 
insulin adherence (adherence), use of SMBG (often done), blood glucose variability (mean 3.89) and the 
follow-up time (24 months); 
‡ Logit (link function) and binomial distribution were used to produce transition probabilities of SH with SAS 
GENMOD when the models for RR could not converge. 
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Table V-A 3: Relative risk of severe hypoglycemia (SH) on subsequent SH episodes in three 
subsequent observation windows in the DCCT  
Treatment 
Assignment 
Observed windows 
after index SH 
Unadjusted RR ( 95% CI)* Adjusted RR  (95% CI) † 
Intensive 
Therapy Months 1-3   
  Prior SH  1.65(1.36,2.00) 1.70(1.48, 1.97) 
  No prior SH 1.00(reference) 1.00(reference) 
 Months 4-6   
  Prior SH  1.29(1.02, 1.63) 1.45(1.20, 1.74) ‡ 
  No prior SH 1.00(reference) 1.00(reference) 
 Months 7-9   
  Prior SH  1.29(1.03, 1.61) 1.36(1.16, 1.61) 
  No prior SH 1.00(reference) 1.00(reference) 
    
Conventional 
Therapy Months 1-3   
  Prior SH  3.88(2.33, 6.48) 3.38(2.21, 5.18) 
  No prior SH 1.00(reference) 1.00(reference) 
 Months 4-6   
  Prior SH  1.36(0.47, 3.99) 1.37(0.76,2.47) ‡ 
  No prior SH 1.00(reference) 1.00(reference) 
 Months 7-9   
  Prior SH  1.69(0.82, 3.44) 1.95(1.33, 2.87) 
  No prior SH 1.00(reference) 1.00(reference) 
* Unadjusted RRs were the estimates which had been considered for a correlation within one patient;  
†Adjusted following covariates in the models: Gender, baseline age, duration of disease and history of SH when 
patients entered the DCCT, most recent and incidence rates of SH episodes up to the occurrence of prior SH, 
expected and actual A1C, alcohol use, physical activities, meal plan and insulin adherence, use of self-
monitoring blood glucose (SMBG), blood glucose variability (standard deviation calculated from 7-point blood 
glucose profiles for individual patient) and follow-up time since entry of the DCCT; 
‡Incidence rate ratio was used to approximate RR when the models for RR could not converge. 
 
 
 
 
      
B. Severe hypoglycemia and subsequent weight gain in patients with type 1 diabetes 
1. Introduction 
Intensification of insulin therapy in type 1 diabetes often results in weight gain [4]. In 
the DCCT, which randomized type 1 diabetic patients to either intensive or conventional 
therapy, the prevalence of overweight, defined as the BMI over 27.8kg/m2 for men and 
27.3kg/m2 for women, reached 33% in the intensive therapy group compared with 19% in 
the conventional therapy group after an average 6.5 year follow-up [18].  
A number of possible mechanisms have been described to explain weight gain on 
insulin therapy, including compensation for hypoglycemia [4]. The unpleasant symptoms 
and negative consequences of hypoglycemia may result in significant fear of hypoglycemia 
[17]. Because low blood glucose levels can be remedied by ingestion of glucose or food 
following a hypoglycemic event, patients may over-react by consuming or be instructed to 
consume more calories (e.g., frequent snacking) in response to the threat of subsequent 
hypoglycemia.  
However, there is very limited direct evidence to support this hypothesis of 
compensation for hypoglycemia. An early DCCT study [25] using patients recruited in the 
first year reported that the 29 patients who experienced severe hypoglycemia (SH) gained 
more weight than those without SH in the intensive therapy arm, but not for the conventional 
therapy arm.  Another study ,which re-analyzed data from a 26-week, randomized, open-
label trial comparing insulin detemir with NPH insulin in 476 patients with type 2 diabetes 
[26],  reported only P values for the correlations between the frequencies of hypoglycemia 
and weight gain and concluded that hypoglycemia was a predictor of weight gain with NPH 
insulin, but not with insulin detemir. However, the temporal relation between occurrence of 
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SH or hypoglycemia and weight gain was unclear in these studies because some of the 
weight gain may have occurred before the first SH or hypoglycemic episode.  
The aims of this study are: 1) to examine the effects of SH on subsequent weight 
change/actual weight over various periods following SH episodes; 2) to estimate the effects 
of SH on the risk of substantial weight gain, overweight, and obesity in patients with type 1 
diabetes.  
2. Methods 
Participants and study population 
We used data from the DCCT, which randomized 1,441 patients between ages of 13 
to 39 with duration of type 1 diabetes ranging 1-15 years to either intensive therapy or 
conventional therapy between 1983 and 1993. Patients were followed through quarterly 
visits over an average of 6.5 years [31].  In the trial, registered dietitians tailored meal plans 
and educational strategies to the need and life style of each individual to achieve and 
maintain ideal body weight with goals of 15-20% of energy from protein, 30-35% from fat, 
and 50-55% from carbohydrates. Patients in the intensive therapy group received more 
frequent and detailed instruction on individualized meal plans. Since weight gain with 
intensive therapy had been recognized, dietitians increased their emphasis and counseling 
on weight management for patients in the intensive therapy group, and greater attention was 
given to the relation between nutrient intake and insulin to try to achieve target glycemic 
levels without hypoglycemia or weight gain [31]. 
For our analyses, we restricted eligible patients to be 18 years or older when they 
entered the trial to avoid weight gain as a result of adolescent growth.  In addition, we 
censored female patients at the time of their first pregnancy during follow-up based on their 
reported last menstrual period dates. 
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The public health institutional review board of University of North Carolina approved 
this study and all study participants in the DCCT have given written informed consent.  
Definition of SH 
SH was defined as an episode in which a patient required assistance of another 
person and the following conditions: 1) a blood glucose level of < 50mg/dl, or 2) prompt 
recovery following oral carbohydrate, intravenous glucose, or glucagons. Patients in the 
DCCT were instructed to report all episodes of suspected SH immediately, and all were 
interviewed to verify each episode [31]. 
Weight measurement  
Weight was measured at baseline and each quarterly examination [27]. Weight (in 
kilograms) was measured with the patients in light clothing and stockings on the same 
balance-beam scale for the duration of the DCCT trial. Overweight was defined as BMI 
values ≥25.0, and obesity were defined as BMI values ≥30.0 [33].  
Estimation of the effects of SH on subsequent weight gain over various periods 
We estimated the effects of SH (index SH), occurring in a quarterly interval, on 
weight during the following one, two, three, four, eight, and twelve consecutive quarterly 
visits (intervals). Each patient could contribute multiple observations (figure 1). The different 
numbers of involved quarterly intervals approximated the observation periods with various 
durations from 3 months to 36 months after SH episodes. The comparison intervals were 
those without occurrence of index SH. Two continuous outcome variables were defined for 
each observation period: 1) the first outcome variable (weight change) was the difference 
between the weight measured at the end of the observation period and the weight at the 
beginning of the same observation period; 2) the second was the actual weight measured at 
the end of the observation period.  Besides using various observation periods after index SH, 
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we also looked at the effects of index SH on weight change in three subsequent fixed-term 
time windows during the 1st, 2nd and 3rd quarterly interval following index SH (the observation 
period for each time window approximated a 3-month period in this analysis), and the 
outcome as the weight change in this analysis was the quarterly weight change for three 
intervals, respectively.  
We controlled for confounding by including a set of a priori specified covariates in the 
models based on directed acyclic graph [38](Figure 7): 1) time-independent variables: 
gender, baseline age (3 categories “18-25, 26-29, and >29 years of old ”), duration of type 1 
diabetes (3 categories “1-5, 6-10 and >10 years”) at the DCCT baseline and history of SH 
prior to the entry of the DCCT (dichotomized variable based on the DCCT baseline file); 2) 
time-dependent variables: recent SH (dichotomized variable to indicate the occurrence of 
SH in the quarterly interval prior to index SH), and rates of SH episodes from baseline to 
prior to the index SH (3 categories “no occurrence prior to the index SH, less or equal to the 
90th percentile of the rates in corresponding treatment groups, and greater than 90th 
percentile”), physical activity (3 categories “little, moderate and strenuous” based on annual 
questionnaire), meal plan adherence (dichotomized variable for whether subjects claimed to 
have followed the meal plan almost all of the time in quarterly questionnaire), insulin 
adherence (dichotomized variable for whether subjects claimed to have followed the 
prescribed insulin dose in quarterly questionnaire), BMI prior to SH (a restricted quadratic 
spline with 3 knots at BMI 18.5, 25 and 30kg/m2, corresponding to normal weight, 
overweight and obesity), quarterly daily insulin dose (a restricted quadratic spline with 3 
knots at 5th , 50th  and 95th percentiles) and follow-up time since entry of the DCCT (a 
restricted cubic spline with 5 knots at 5th , 10th , 25th , 75th  and 95th percentiles).  We 
categorized continuous covariates or created the knots for their splines based on 
established cut-points (e.g., BMI) or known conventions. Otherwise, we used empirical cut-
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points based on the actual distributions from data themselves (e.g., the different distribution 
percentiles). We used multivariable linear regression to estimate the association between 
the index SH and subsequent weight gain. Because each patient could contribute multiple 
observations, we used GEE with a linear link, normal variance function, and exchangeable 
working correlation to allow for the dependence of observations within a person [28, 29]. 
Estimation of the effects of SH on substantial weight gain, overweight, and obesity 
We used Cox proportional hazard models to estimate hazard ratio (HRs) for time to 
first substantial weight gain (defined as the 5, 10, 15 and 20% weight gain from baseline, 
respectively), becoming overweight, and becoming obese, comparing patients after they had 
their first SH episode with all patients who did not experience any SH episode at the same 
time during follow-up (they could have a SH episode later during follow-up) [30]. Hence, the 
exposure in the Cox models was a time-dependent variable: 1) the patient was defined as 
unexposed prior to the 1st SH episode; 2) after the 1st SH episode, the patient was defined 
as always exposed. We checked the proportional hazards assumption by adding an 
interaction term between the exposure and the follow-up time. We controlled for 
confounding by including a set of a priori specified covariates in the models based on a 
directed acyclic graph [38]( Figure 8) : 1) time-independent variables: gender, baseline age 
(a restricted quadratic spline with 3 knots at 5th, 50th  and 95th percentiles ), duration of type 
1 diabetes (a restricted quadratic spline with 3 knots at 5th , 50th  and 95th percentiles), 
history of SH (same definition above) and BMI (continuous variable) at baseline; 2) time-
dependent variables: average physical activity (dichotomized variable on whether a subject 
had strenuous activities in 80%  of follow-up time or more, updated annually), average meal 
plan adherence (dichotomized  variable on whether a subject had claimed to follow meal 
plan in 80% of follow-up time or more, updated quarterly) and average daily insulin dose (a 
restricted quadratic spline with 3 knots at 5th , 50th  and 95th percentiles, updated quarterly). 
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Average daily insulin dose may be seen as a time-dependent confounder affected by 
prior SH (Figure 9). Under this assumption, the Cox model controlling for average daily 
insulin dose as well as a model not controlling for it would be biased [40]. As an ancillary 
analysis, we therefore used marginal structural models (MSM) that allow us to control for 
average daily insulin dose that may be affected by prior SH. We used weighted pooled 
logistic regression models to approximate the parameters of the MSM [13].  This involved 
three sets of models: 1) a pooled logistic model estimating the time-varying exposure 
propensity (the probabilities of having the first SH episode during the follow-up), 2) a pooled 
logistic model estimating the probability of censoring, and 3) the final model weighting 
exposed and unexposed by the weights obtained in steps 1) and 2) to obtain the estimates 
for the main exposure with robust standard errors for the confidence intervals. To estimate 
the time-dependent intercept for all three models in the MSM, we produced a restricted 
cubic spline for the follow-up time (the numbers of months since start of the trial) with the 
SAS macro RCSPLNE [42]. We also examined the distribution of the estimated weights to 
check whether the weights were well constructed (the well-constructed weights should have 
a mean around one and narrow ranges for the estimated weights) [41].     
3. Results 
We identified 1,218 eligible patients from both treatment arms in the DCCT who 
contributed 25,336 observation periods for final analysis (the exact eligible number of 
patients varied by observation periods with various durations, see footnotes in table 1). 
Periods with prior SH events had higher daily insulin doses than periods without SH in both 
treatment arms (Table V-B 1).  
In the intensive therapy arm, the estimated effects of index SH on subsequent weight 
change and weight were close to the null effect (zero for the difference of the means for 
weight change or for difference of the means for weight) comparing to those without index 
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SH (table 2-3). In the conventional therapy arm, however, occurrence of SH appeared to be 
associated with a weight loss and less weight up to 12 months after the index SH (Table V-B 
2,Table V-B 3). The effect sizes of weight loss for both outcome variables were quite 
constant over various periods following occurrence of SH: the adjusted differences of the 
means for weight change were -0.29 (95% CI: -0.51, -0.08) and -0.46 (-0.83, -0.09) in the 
observation period months 1-3 and 1-12 respectively, and the corresponding adjusted 
differences of the means for  weight were -0.43 (-0.70, -0.16) and -0.43 (-0.77, -0.09). The 
results from the analysis for the effects of index SH on the quarterly weight change in three 
fixed-term time windows further showed that the observed weight loss in the conventional 
therapy arm happened only in the 1st 3-month period after index SH (Table V-B 4) but weight 
change were observed close to null effect in the 2nd time window (months 4-6) and the 3rd 
time window (months 7-9) following index SH. The adjusted differences of the means for 
weight change were -0.04 (-0.24, 0.17) and -0.04 (-0.23, 0.15) for the 2nd and 3rd time 
windows, respectively.  
The estimated HRs for the occurrence of SH on substantial weight gain, becoming 
overweight or obese were also around the null effect (HR=1) in both treatment arms (Table 
V-B 5, 6-11). In the intensive therapy arm, the adjusted HRs were 0.94 (0.69, 1.30) and 1.07 
(0.71, 1.64) for becoming overweight and obese following the first SH during follow-up, 
respectively. The corresponding HRs were 1.11 (0.71, 1.72) and 1.20 (0.52, 2.79) in the 
conventional therapy arm. The estimates obtained from Cox models and MSM were similar. 
We obtained well-behaved weights with the mean around one with a maximum weight of 
5.82 in MSM models (Table V-B 12).    
4. Discussion 
Intensification of insulin therapy in type 1 diabetes often results in weight gain [4]. 
Furthermore, excessive weight gain in type 1 diabetes was found in DCTT to affect patients’ 
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cardiovascular risk profile with adverse change in lipid and blood pressure levels [7]. 
Identifying risk factors contributing to excessive weight gain, especially modifiable factors 
may help to identify ways to improve clinical management of type 1 diabetes to prevent 
excessive weight gain in patients with type 1 diabetes on insulin therapy. 
The results in this study do not provide evidence to support an association between 
SH episodes and subsequent weight gain using both weight change and actual weight as 
outcome variables. Instead, in the conventional therapy group, a small, short-term weight 
loss was found following SH episodes. Furthermore, our results also found little or no effect 
of occurrence of SH on substantial weight gain, becoming overweight or obese in the DCCT 
population.  
We cannot readily explain why we observed a weight loss after occurrences of SH in 
patients in the conventional therapy arm. One plausible explanation for such weight loss 
could be due to a decrease of insulin dose in response to occurrences of SH. Although a 
slight decrease of insulin dose after occurrence of SH was observed in both treatment 
groups in the DCCT, occurrence of SH appeared to have greater effects on ≥10% decrease 
of insulin dose in the conventional therapy arm than in the intensive therapy (results not 
shown).  
Because the occurrence of SH may lead to a decrease of insulin dose to raise 
patients’ blood glucose levels, average daily insulin dose would be an intermediate covariate 
and confounder simultaneously. The similar estimates from the Cox and the MSM models 
seem to suggest that average daily insulin dose is not a major intermediate covariate 
between SH and weight gain in the DCCT. However, it should be noted that the insulin 
information was available only quarterly and based on self-report from patients in the DCCT 
data [27]. Therefore, any temporary changes on insulin dose in response to SH may not be 
captured by the quarterly insulin information.  
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This study has several limitations with regard to available information for our 
research questions and extrapolating our findings to other patients with type 1 diabetes. In 
the DCCT, no information on daily insulin dose is available, and we had to rely on quarterly 
data for insulin dose. We were only able to study severe cases of hypoglycemia and we do 
not know whether our findings would apply to less severe episodes. The availability of only 
quarterly information and limited sample size also impeded our attempt to further explore the 
relationship between the frequencies of SH and weight gain in this population. Because the 
DCCT is a clinical trial, patients in the DCCT likely had stricter diets and weight 
management compared with the patients in routine clinical care; the patients also received 
more dietary counseling that would occur in routine practice. Thus, patients were likely to be 
more adherent to their medical and diet regimen [31]. In our analysis, we cannot disentangle 
underlying causal mechanisms (overreaction to SH by consuming more calories vs. other 
unknown mechanisms) due to limited information on diet and physical activity. The DCCT 
study was conducted over 25 years ago and our results may not be generalizable to current 
patients with type 1 diabetes.  However, the results in our study imply that adverse effects of 
SH on weight gain, if such association exists in other type 1 diabetic populations, may be 
avoidable under a strict diet and weight management.  
Notwithstanding these limitations, we were able to utilize longitudinal information in 
the DCCT in our analysis. We also designed our study to address the temporality of SH 
episodes as a risk factor for subsequent weight gain. To our knowledge, our study is the first 
one to systematically test the association between the occurrence of SH and weight gain 
using various design and analytic methods including repeated observations, survival 
analysis and MSM models in a type 1 diabetic cohort. 
In summary, our study did not find evidence to support an association between 
occurrence of SH and subsequent weight gain in patients with type 1 diabetes. Because the 
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DCCT is a clinical trial, we should be cautious about generalizing our findings to patients 
with type 1 diabetes in general.  However, our findings imply that adverse effects of SH on 
weight gain, if such association exists in other type 1 diabetic populations, may be avoidable 
under a strict diet and weight management.  
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Table V-B 1: Number of available observation periods with various observation durations 
and the distributions of some covariates by exposure status --occurrence of severe 
hypoglycemia (SH) in the DCCT
a
 
  Intensive Therapy Conventional Therapy 
  SH No SH SH No SH 
Available 
observation periods 
     
 Months 1-3 
b
 1,308 11,275 403 12,350 
 Months 1-6  
b
 1,231 10,748 383 11,756 
 Months 1-9  
b
 1,175 10,204 366 11,164 
 Months 1-12  
b
 1,117 9,664 352 10,570 
 Months 1-24  
b
 892 7,532 289 8,239 
 Months 1-36  
b
 639 5,525 217 5,971 
Covariates for 
observation period 
months 1-3 
c
 
     
 
Mean daily insulin dose 
(SD) 
d
 
54.0 (19.0) 50.8 (19.1) 50.6 (16.6) 46.4 (15.0) 
 Mean BMI (SD) 25.2 (3.4) 25.3 (3.5) 24.6 (2.8) 24.6 (3.0) 
 Physical activities (%)     
 Strenuous 5.3 5.3 11.2 6.7 
 Moderate 59.1 53.6 50.3 53.1 
 Little 35.6 41.1 38.5 40.2 
 Meal plan adherence (%)     
 Yes 85.0 83.2 79.8 80.4 
 No 15.0 16.8 20.2 19.6 
 Insulin use adherence (%)     
 Yes 77.1 79.2 87.9 87.7 
 No 22.9 20.8 12.1 12.3 
a
 The numbers of eligible patients for the observation periods with various durations: months 
1-3  (604 from intensive therapy [IT] and 614 from conventional therapy [CT]), months 1-6  
(600 from IT and 609 from CT), months 1-9 (598 from IT and 608 from CT), months 1-12 
(596 from IT and 603 from CT), months 1-24  (574 from IT and 603 from CT), and months 
0-36  (553 from IT and 576 from CT);  
b
 Durations were only approximated by number of composed consecutive quarterly intervals 
after occurrence of SH; 
c
 The covariate distributions for other observation periods were similar to months 1-3; 
d
 International unit for insulin. 
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Table V-B 2: Effects of severe hypoglycemia (SH) on subsequent weight change in kilogram 
in various observation periods in the DCCT   
Treatment 
Assignment 
/durations after 
SH (months) 
Unadjusted mean for weigh change (95% 
CI) by SH status 
a
 
Unadjusted 
difference of the 
means for  weight 
change (95% CI) 
c
 
Adjusted difference 
of the means for  
weight change 
(95% CI) 
c, d
 
Yes No 
Intensive 
Therapy 
    
1-3
b
 0.27 (0.16, 0.29) 0.32 (0.29, 0.35) -0.05 (-0.17, 0.06) -0.04 (-0.16, 0.09) 
1-6 
b
 0.58 (0.43, 0.73) 0.64 (0.58, 0.70) -0.07(-0.22, 0.09) -0.04 (-0.20, 0.12) 
1-9 
b
 0.85 (0.63, 1.07) 0.96 (0.87, 1.05) -0.11 (-0.33, 0.12) -0.09 (-0.31, 0.14) 
1-12 
b
 1.24 (1.00, 1.48) 1.25 (1.13, 1.37) 0.00 (-0.24, 0.22) 0.09 (-0.11, 0.3) 
1-24 
b
 2.39 (2.00, 2.78) 2.51 (2.26, 2.76) -0.12 (-0.45, 0.22) 0.00 (-0.31, 0.29) 
1-36 
b
 3.27 (2.78, 3.76) 3.69 (3.32, 4.05) -0.41 (-0.81, -0.02) -0.33 (-0.70, 0.05) 
Conventional 
Therapy 
    
1-3
b
 -0.15 (-0.35, 0.05) 0.16 (0.13, 0.19) -0.31 (-0.52, -0.10) -0.29 (-0.51, -0.08) 
1-6 
b
 -0.06 (-0.30, 0.17) 0.28 (0.24, 0.32) -0.35 (-0.59, -0.10) -0.34 (-0.60, -0.09) 
1-9 
b
 0.00 (-0.32, 0.32) 0.42 (0.36, 0.48) -0.42 (-0.74, -0.09) -0.41 (-0.73, -0.09) 
1-12 
b
 -0.03 (-0.39, 0.33) 0.55 (0.46, 0.63) -0.58 (-0.93, -0.22) -0.46 (-0.83, -0.09) 
1-24 
b
 0.62 (0.22, 1.02) 1.08 (0.91, 1.26) -0.47 (-0.84, -0.09) -0.14 (-0.52, 0.23) 
1-36 
b
 1.06 (0.52, 1.59) 1.58 (1.32, 1.84) -0.52 (-0.99, -0.05) -0.18 (-0.64, 0.28) 
a 
The estimates had been addressed  the correlation within one patient but did not include 
other covariates; 
b
 Observation durations were only approximated by number of composed consecutive 
quarterly intervals after occurrence of SH. 
c
 The difference was the difference between the mean for weight change after occurrence of 
SH and the mean without SH for the corresponding observation period. 
d
 Adjusted covariates included: Gender, baseline age, duration of disease, baseline history of 
SH, most recent and incidence rates of SH prior to index SH, BMI, daily insulin dose, 
exercise activities, insulin adherence, meal plan adherence and follow-time. 
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Table V-B 3: Effects of severe hypoglycemia (SH) on subsequent weight in kilogram in 
various observation periods in the DCCT   
Treatment 
Assignment 
/durations after 
SH (months) 
Unadjusted mean for weigh  (95% CI) by 
SH status 
a
 
Unadjusted 
difference of the 
means for weight 
(95% CI) 
c
 
Adjusted difference 
of the means for  
weight  
(95% CI) 
c, d
 
Yes No 
Intensive 
Therapy 
    
1-3
b
 75.4 (74.3, 76.5) 75.1 (74.1, 76.2) 0.25 (-0.04, 0.54) 0.00 (-0.17, 0.17) 
1-6 
b
 75.6 (74.5, 76.7) 75.4 (74.3, 76.4) 0.21 (-0.07, 0.50) 0.04 (-0.15, 0.23) 
1-9 
b
 75.7 (74.6, 76.8) 75.6 (74.5, 76.6) -0.10 (-0.17, 0.38) 0.01 (-0.19, 0.22) 
1-12 
b
 75.9 (74.8, 77.0) 75.8 (74.9, 76.8) 0.11 (-0.16, 0.37) 0.13 (-0.08, 0.33) 
1-24 
b
 76.5 (75.4, 77.6) 76.5 (75.4, 77.6) 0.00 (-0.30, 0.29) 0.09 (-0.15, 0.33) 
1-36 
b
 77.1 (76.0, 78.3) 77.5 (76.3, 78.6) -0.37 (-0.66, -0.08) -0.08 (-0.38, 0.21) 
Conventional 
Therapy 
    
1-3
b
 73.7 (72.7, 74.7) 73.8 (72.8, 74.8) -0.06 (0.14, -0.34) -0.43 (-0.70, -0.16) 
1-6 
b
 73.8 (72.7, 74.8) 73.9 (72.9, 74.9) -0.15 (-0.45, -0.14) -0.43 (-0.72, -0.14) 
1-9 
b
 73.8 (72.8, 74.8) 74.0 (73.0, 75.0) -0.23 (-0.53, 0.07) -0.43 (-0.75, -0.10) 
1-12 
b
 73.8 (72.7, 74.8) 74.1 (73.1, 75.1) -0.31 (-0.62, 0.00) -0.43 (-0.77, -0.09) 
1-24 
b
 74.4 (73.3, 75.4) 74.5 (73.5, 75.5) -0.08 (-0.36, 0.20) -0.10 (-0.36, 0.17) 
1-36 
b
 74.8 (73.7, 75.9) 74.9 (73.9, 76.0) -0.15 (-0.54, 0.25) -0.11(-0.53, 0.31) 
a 
The estimates had been addressed the correlation within one patient but did not include 
other covariates; 
b
 Observation durations were only approximated by number of composed consecutive 
quarterly intervals after occurrence of SH. 
c
 The difference was the difference between the mean for weight after occurrence of SH and 
the mean without SH for the corresponding observation period. 
d
 Adjusted covariates included: Gender, baseline age, duration of disease, baseline history of 
SH, most recent and incidence rates of SH prior to index SH, BMI, daily insulin dose, 
exercise activities, insulin adherence, meal plan adherence and follow-time. 
 
 
 
 
61 
 
Table V-B 4: Effects of severe hypoglycemia (SH) on subsequent weight change in kilogram 
in three consecutive quarterly windows in the DCCT   
Treatment 
Assignment /time 
window after SH 
(months) 
Unadjusted mean for weigh change (95% 
CI) by SH status 
a
 
Unadjusted 
difference of the 
means for  weight 
change (95% CI) 
c
 
Adjusted difference 
of the means for  
weight change 
(95% CI) 
c, d
 
Yes No 
Intensive 
Therapy 
    
1-3
b
 0.27 (0.16, 0.29) 0.32 (0.29, 0.35) -0.05 (-0.17, 0.06) -0.04 (-0.16, 0.09) 
4-6 
b
 0.26 (0.16, 0.36) 0.30 (0.27, 0.33) -0.04 (-0.15, 0.07) -0.01 (-0.13, 0.12) 
7-9 
b
 0.22 (0.09, 0.35) 0.29 (0.26, 0.32) -0.07 (-0.21, 0.07) -0.06 (-0.21, 0.10) 
Conventional 
Therapy 
    
1-3
b
 -0.15 (-0.35, 0.05) 0.16 (0.13, 0.19) -0.31 (-0.52, -0.10) -0.29 (-0.51, -0.08) 
4-6 
b
 0.04 (-0.19, 0.27) 0.14 (0.11, 0.17) -0.10 (-0.34, 0.14) -0.04 (-0.24, 0.17) 
7-9 
b
 0.03 (-0.15, 0.22) 0.15 (0.12, 0.18) -0.12 (-0.32, 0.08) -0.04 (-0.23, 0.15) 
a 
The estimates had been addressed the correlation within one patient but did not include 
other covariates; 
b
 Observation windows were only approximated by quarterly intervals after occurrence of SH. 
c
 The difference was the difference between the mean for weight change after occurrence of 
SH and the mean without SH for the corresponding time windows. 
d
 Adjusted covariates included: Gender, baseline age, duration of disease, baseline history of 
SH, most recent and incidence rates of SH prior to index SH, BMI, daily insulin dose, 
exercise activities, insulin adherence, meal plan adherence and follow-time. 
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Table V-B 5:  Summary of results for effects of severe hypoglycemia (SH) on risk of 
substantial weight gain, overweight and obesity in the DCCT 
Treatment 
Assignment 
Models with different 
outcomes 
Adjusted HR 
(95% CI) 
MSM
a
 HR 
(95% CI) 
Intensive Therapy    
 5% weight gain 0.99 (0.79, 1.24) 1.01 (0.79, 1.29) 
 10% weight gain 1.09 (0.87, 1.36)
b
 1.12 (0.88, 1.43) 
 15% weight gain 0.89 (0.68, 1.16) 0.91 (0.69, 1.2) 
 20% weight gain 0.92 (0.66, 1.28)
 b
 0.89 (0.63, 1.26) 
 Overweight 0.94 (0.69, 1.3) 0.92 (0.64, 1.32) 
 Obesity 1.07 (0.71, 1.64) 1.12 (0.72, 1.75) 
Conventional Therapy    
 5% weight gain 1.15 (0.87, 1.53) 1.10 (0.82, 1.48) 
 10% weight gain 1.06 (0.78, 1.46) 1.09 (0.76, 1.54) 
 15% weight gain 1.19 (0.75, 1.90) 1.11 (0.65, 1.89) 
 20% weight gain 1.11 (0.49, 2.51) ----
c
 
 Overweight 1.11 (0.71, 1.72) 1.07 (0.69, 1.64) 
 Obesity 1.20 (0.52, 2.79) 1.18 (0.46, 3.02) 
a
 MSM stands for marginal structural model. 
b
 P value<0.15 for Cox test for proportion assumption.  
c
 MSM did not converge 
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Table V-B 6: Occurrence of severe hypoglycemia (SH) on 5% weight gain during the 
follow-up in the DCCT 
    
Hazard Ratio 
Treatment 
Assignment  
No. of 
Event 
Quarterly 
Follow up 
intervals 
Unadjusted 
(95% CI) 
Adjusted 
(95%CI) 
MSM
a
 
 (95% CI) 
Intensive 
Therapy       
 
SH 130 1248 1.07 (0.87, 1.33) 0.99 (0.79, 1.23) 1.01 (0.79, 1.29) 
 
No SH 403 2661 1 1 1 
Conventional 
Therapy       
 
SH 63 960 1.11 (0.84, 1.45) 1.15 (0.87, 1.53) 1.1 (0.82, 1.48) 
 
No SH 391 5397 1 1 1 
a
 MSM stands for marginal structural model. 
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Table V-B 7: Occurrence of severe hypoglycemia (SH) on 10% weight gain during the 
follow-up in the DCCT 
    
Hazard Ratio 
Treatment 
Assignment  
No. of 
Event 
Quarterly 
Follow 
up 
intervals 
Unadjusted 
(95% CI) 
Adjusted 
(95%CI) 
MSM
a
 
 (95% CI) 
Intensive 
Therapy       
 
SH 160 3015 1.1 (0.89, 1.37) 1.08 (0.86, 1.35)
b
 1.12 (0.88, 1.43) 
 
No SH 244 4570 1 1 1 
Conventional 
Therapy       
 
SH 57 2027 1.15 (0.85, 1.56) 1.06 (0.78, 1.46) 1.09 (0.76, 1.54) 
 
No SH 197 8390 1 1 1 
a
 MSM stands for marginal structural model. 
b
 P value<0.15 for Cox test for proportion assumption 
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Table V-B 8: Occurrence of severe hypoglycemia (SH) on 15% weight gain during the 
follow-up in the DCCT 
    
Hazard Ratio 
Treatment 
Assignment  
No. of 
Event 
Quarterly 
Follow up 
intervals 
Unadjusted 
(95% CI) 
Adjusted 
(95%CI) 
MSM
a
 
 (95% CI) 
Intensive 
Therapy       
 
SH 152 5783 0.89 (0.69, 1.15) 0.89 (0.68, 1.16) 0.91 (0.69, 1.2) 
 
No SH 109 4313 1 1 1 
Conventional 
Therapy       
 
SH 28 2651 1.28 (0.82, 2.01) 1.21 (0.76, 1.92) 1.11 (0.65, 1.89) 
 
No SH 74 9720 1 1 1 
a
 MSM stands for marginal structural model. 
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Table V-B 9: Occurrence of severe hypoglycemia (SH) on 20% weight gain during the 
follow-up in the DCCT 
    
Hazard Ratio 
Treatment 
Assignment  
No. of 
Event 
Quarterly 
Follow 
up 
intervals 
Unadjusted 
(95% CI) 
Adjusted 
(95%CI) 
MSM
a
 
 (95% CI) 
Intensive 
Therapy       
 
SH 81 5169 0.90 (0.66, 1.25) 0.92 (0.66, 1.28)
 b
 0.89 (0.63, 1.26) 
 
No SH 83 6390 1 1 1 
Conventional 
Therapy       
 
SH 9 2902 1.17 (0.54, 2.57) 1.12 (0.51, 2.51) ----c 
 
No SH 23 10138 1 1 1 
a
 MSM stands for marginal structural model. 
b
 P value<0.15 for Cox test for proportion assumption  
c
 MSM did not converge 
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Table V-B 10: Occurrence of severe hypoglycemia (SH) on becoming overweight during the 
follow-up in the DCCT 
    
Hazard Ratio 
Treatment 
Assignment  
No. of 
Event 
Quarterly 
Follow up 
intervals 
Unadjusted 
(95% CI) 
Adjusted 
(95%CI) 
MSM
a
 
 (95% CI) 
Intensive 
Therapy       
 
SH 80 2,538 0.97 (0.72, 1.31) 0.94 (0.69, 1.3) 0.92 (0.64, 1.32) 
 
No SH 165 3,284 1 1 1 
Conventional 
Therapy       
 
SH 27 1,276 0.92 (0.6, 1.4) 1.11 (0.71, 1.72) 1.07 (0.69, 1.64) 
 
No SH 151 5,099 1 1 1 
a
 MSM stands for marginal structural model. 
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Table V-B 11: Occurrence of severe hypoglycemia (SH) on becoming obesity during the 
follow-up in the DCCT 
    
Hazard Ratio 
Treatment 
Assignment  
No. of 
Event 
Quarterly 
Follow up 
intervals 
Unadjusted 
(95% CI) 
Adjusted 
(95%CI) 
MSM
a
 
 (95% CI) 
Intensive 
Therapy       
 
SH 48 5200 0.82 (0.55, 1.21) 1.07 (0.71, 1.64) 1.12 (0.72, 1.75) 
 
No SH 69 6305 1 1 1 
Conventional 
Therapy       
 
SH 8 2685 1.09 (0.49, 2.43) 1.20 (0.52, 2.79) 1.18 (0.46, 3.02) 
 
No SH 37 9669 1 1 1 
a
 MSM stands for marginal structural model. 
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Table V-B 12: Distributions of estimated weights in marginal structural models for outcomes 
as substantial weight gain, overweight and obesity in the DCCT 
  
Estimated weights 
Treatment 
Assignment 
Models with different 
outcomes 
Mean(SD) Minimum Maximum 
Intensive Therapy 
    
 
5% weight gain 0.99 (0.11) 0.62 2.15 
 
10% weight gain 1.00 (0.16) 0.56 3.16 
 
15% weight gain 1.00 (0.18) 0.21 4.08 
 
20% weight gain 1.00 (0.16) 0.45 3.64 
 
Overweight 1.00 (0.18) 0.44 2.88 
 
Obesity 1.00 (0.17) 0.24 2.44 
Conventional Therapy 
    
 
5% weight gain 1.01 (0.21) 0.3 4.74 
 
10% weight gain 1.00 (0.24) 0.35 5.78 
 
15% weight gain 1.00 (0.26) 0.26 5.76 
 
20% weight gain 1.00 (0.26) 0.32 5.82 
 
Overweight 0.99 (0.27) 0.37 5.43 
 
Obesity 1.00 (0.25) 0.46 5.51 
 
 
 
 
 
 
 
 
 
 
      
C. Change in insulin dose in response to severe hypoglycemia in the Diabetes 
Control and Complication Trial 
1. Introduction 
We re-analyzed the Diabetes Control and Complication Trial (DCCT) data to 
estimate the quantitative association between occurrence of severe hypoglycemia (SH) and 
change of insulin dose as a supplementary analysis to assist interpretation of the results 
from study aim 1 and aim 2.  
2. Methods 
Study population 
We used data from the Diabetes Control and Complications Trial (DCCT), which 
randomized 1,441 patients between ages of 13 to 39 with duration of type 1 diabetes 1-15 
years to either intensive therapy or conventional therapy between 1983 and 1993.  
We only included quarterly visits after the first year of follow-up in this analysis. We 
also restricted eligible patients who must be 18 years or older when they entered the trial, 
and censored female patients at the time of their first pregnancy during follow-up based on 
their reported last period dates. 
Definition of SH 
SH was defined as an episode in which a patient required assistance of another 
person and the following conditions: 1) a blood glucose level of < 50 mg/dl, or 2) prompt 
recovery following oral carbohydrate, intravenous glucose, or glucagons. Patients in the 
DCCT were instructed to report all episodes of suspected SH immediately, and all were 
interviewed to verify each episode [31]. The first SH was defined as the first SH episode 
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occurring during the DCCT follow-up, and the repeated SH was the any episodes after the 
first SH during the DCCT follow-up. 
Definition of analytic unit for this analysis 
Daily changes of therapy regimens in the DCCT were not centrally documented and 
were not accessible for analysis, and only typical daily insulin doses (TDID) for the past 
quarterly interval were recorded at each quarterly visit [31]. Thus, in the DCCT there is no 
way to tell whether the reported dose actually reflected the dose before occurrence of SH or 
after occurrence of SH if patients had occurred SH episodes in a quarterly interval. To 
account for this issue and conduct this supplementary analysis, new study analytic units 
were constructed and each analytic unit consisted of two consecutive quarterly visits to 
account for temporality of change of insulin dose following occurrence of SH (Figure 5). We 
defined two types of outcomes in each analytic unit: 1) continuous outcome (the difference 
of daily insulin doses between the end and beginning of the analytic unit); and 2) 
dichotomized outcome (≥ 10% dose reduction). 
Statistical analyses 
We used linear multivariable models to estimate the effects of SH occurring in the 
first composed quarterly interval in an analytic unit on the continuous outcome  and used 
log-linear multivariable models to estimate the relative risk (RR) on the dichotomized 
outcome (≥ 10% dose reduction) in each analytic unit. We used generalized estimating 
equations to account for multi-observations per patient and to control relevant factors under 
working correlation structure “exchangeable”. Furthermore, for continuous outcome, we also 
used mixed models as a sensitivity analysis. However, negative variance components were 
reported when we used a random effect for the intercept for each subject by covariance 
structure as either variance component or unstructured in the mixed models. After serial 
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diagnostic tests, we omitted the random effect for the intercept, but correlation within the 
random effect was modeled by including covariance parameter in the residual variance 
matrix R with a toeplitz structure and toep (5) appeared a best fit. 
3. Results 
In the intensive therapy, the effect of SH appeared to be modified by whether the SH 
event was the first SH or the repeated SH for continuous outcome. For the first SH, the 
adjusted difference of mean change of insulin dose (DMID) was -0.25 units (95% CI: -1.90, 
1.41), which was close to null effect (zero). The DMID for the repeated SH was -1.92 units (-
2.82,-1.02) (Table V-C 1).  Results from mixed models also showed the similar pattern. In 
the conventional therapy, a decrease of insulin dose was observed after the both first and 
repeated SH (Table V-C 1).  
In terms of RR for the effect of SH on ≥ 10% dose reduction (dichotomized outcome), 
although the RRs seemed different numerically (RR with 1.19 for the first SH vs. 1.50 for 
repeated SH, Table V-C 2) in the intensive therapy, the heterogeneity test did not reach a 
statistical significance. In the conventional therapy, RRs of SH on ≥ 10% dose reduction for 
the first SH and repeated SH were similar. Furthermore, comparing to those without 
occurrence of SH, the effect of SH on ≥ 10% dose reduction in conventional therapy 
appeared greater than that in the intensive therapy (RR 2.45 for the first SH and 2.64 for the 
repeated SH in the conventional therapy compared to the corresponding RRs 1.19 and 1.50 
in the intensive therapy).   
4. Discussion 
In the DCCT, no information on daily insulin dose is available, and we had to rely on 
quarterly self-reported insulin dose to assume that it was representative of the full quarter for 
individual patients. Furthermore, we had to create new analytic unit by combining two 
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consecutive intervals to estimate the association between the SH and change of insulin 
dose in the DCCT. Otherwise, the temporality between SH and subsequent change of 
insulin dose cannot be determined. 
   The seemingly different response to the first and repeated SH in the intensive 
therapy appears to coincide with the clinical trial design of the DCCT. The primary goal of 
the intensive therapy in the DCCT was to keep A1C as close to normal as possible. 
Although the DCCT did state the need to minimize the risk of SH, clinical staff were required 
to raise blood glucose and A1C target only when the intensive therapy resulted in repeated 
SH. Therefore, the relatively small effect of SH on ≥ 10% dose reduction compared to those 
without SH events in the intensive therapy may reflect that patients in the intensive therapy 
were striving to achieve their glycemic targets whenever they could.   
In summary, the overall reduction of insulin dose following SH appears small in the 
DCCT. In the intensive therapy, no apparent change was observed after the first SH. 
Greater effects of SH on  ≥ 10% dose reduction were observed in the conventional therapy 
than the effects observed in the intensive therapy. 
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Table V-C 1: Occurrence of severe hypoglycemia (SH) on changes of daily insulin doses in 
analytic units by treatment assignments in the DCCT 
1
 
  Intensive Therapy Conventional Therapy 
  Difference of mean changes 
(95% CI) 
Difference of mean changes 
(95% CI) 
1
st
  SH    
 GEE -0.25 (-1.90, 1.41) -3.85 (-5.80, -1.90) 
 Mixed 0.30  (-0.89, 1.48) -2.58 (-3.45, -1.71) 
Repeated SH    
 GEE -1.92 (-2.82, -1.02) -1.79 (-3.23, -0.35) 
 Mixed -1.07 (-1.83, -0.30) -1.66 (-2.50, -0.83) 
P value for 
Heterogeneity Test
2
 
   
 GEE 0.09 0.10  
 Mixed 0.06 0.13 
1
 Covariates in GEE and mixed models: 1) occurrence of SH in current analytic unit, an indicator variable for 
the past experiences of SH during the trial up to but not including the SH occurred in current analytic unit, and 
their interaction term; 2) DCCT baseline variables gender,  age, duration of type 1 diabetes, and history of 
hypoglycemia before entry of the DCCT; 3) ways to administrate insulin (injection /pump); 4) BMI at the 
beginning of the analytic unit; 5) HbA1c and exercise levels at the beginning of the analytic units; and 6) a 
restricted cubic spline with 5 knots for follow-time (months since beginning of the DCCT). 
  
2
 A priori significant level of 0.10 was pre-set for the interaction term between the occurrences of SH in current 
analytic units and the past SH experience during the trials as a statistical heterogeneity test.  
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Table V-C 2: Occurrence of severe hypoglycemia (SH) on effect ≥10% decrease of daily 
insulin doses in analytic units by treatment assignments in the DCCT
1
 
 
 
Intensive Therapy Conventional Therapy 
1
st
  SH 
 
  
 RR of reduction     
(95% CI) 
1.19(0.92, 1.53) 2.45 (1.84, 3.25) 
Repeated SH    
 
RR of reduction      
(95% CI) 
1.50 (1.28, 1.74) 2.64 (1.99, 3.50) 
P value for 
Heterogeneity Test
2
 
 0.13 0.68 
1
 Covariates in GEE model included: 1) occurrence of SH in current analytic unit, an indicator variable for the 
past experiences of SH during the trial up to but not including the SH occurred in current analytic unit, and their 
interaction term; 2) DCCT baseline variables gender,  age, duration of type 1 diabetes, and history of 
hypoglycemia before entry of the DCCT; 3) ways to administrate insulin (injection /pump); 4) BMI at the 
beginning of the analytic unit; 5) HbA1c and exercise levels at the beginning of the analytic units; and 6) a 
restricted cubic spline with 5 knots for follow-time (months since beginning of the DCCT).  
 
2
 A priori significant level of 0.10 was pre-set for the interaction term between the occurrences of SH in current 
analytic units and the past SH experience during the trials as a statistical heterogeneity test.  
 
      
 
VI.CONCLUSIONS 
A. Overview findings 
Hypoglycemia and weight gain are two primary adverse events during insulin therapy 
among patients with type 1 diabetes [1-4]. Hypoglycemia has been documented to be the 
leading limiting factor of intensive diabetes management among patients with type 1 
diabetes mellitus [5, 6]. Hypoglycemia also causes recurrent physical and psychological 
morbidity, higher risk of mortality and impairs defenses against subsequent hypoglycemia 
[1]. Excessive weight gain can not only increase diabetic morbidity and mortality when 
weight gain becomes a barrier to the intensification of insulin treatment, but also adversely 
affect cardiovascular risk profiles as well [4, 7].  
Although prior studies have consistently reported prior SH as a risk factor in general 
for recurrent subsequent SH [9-16], very few studies provide epidemiologic evidence to 
demonstrate the acute effects of SH on subsequent SH in a clinically relevant time range, 
and the magnitude of such effects from population levels in patients with type 1 diabetes is 
not completely clear. The unpleasant symptoms and negative consequences of 
hypoglycemia may result in significant fear of hypoglycemia [17]. Because low blood 
glucose levels can be remedied by ingestion of glucose or food following a hypoglycemic 
event, patients may over-react or be instructed by consuming more calories in response to 
the threat of subsequent hypoglycemia. However, there is very limited direct evidence to 
support this hypothesis of compensation for hypoglycemia. 
We conducted a secondary data analysis using data from the DCCT trial study, and 
the overall objectives of this study are: 1) in a clinically relevant time range, to estimate and 
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illustrate the acute effects of SH on risk of subsequent SH episodes in patients with type 1 
diabetes; 2) to provide insight into the interplay of two primary adverse events (SH and 
weight gain) in patients with type 1 diabetes.  
 The first aim of this study was to estimate the effects of SH (index SH) on 
subsequent SH in three subsequent time windows at months 1-3, 4-6 and 7-9 after index SH 
in patients with type 1 diabetes. The highest absolute risks (transition probabilities) for 
subsequent SH episodes after index SH were observed in the first 3-month observation 
window in both treatment arms in the DCCT. In the conventional therapy, the risks to 
develop subsequent SH episodes in the first 3 months, months 4-6 and months 7-9 after 
index SH were 19.8%, 15.4% and 15.9%, respectively; the corresponding risks were 21.5%, 
21.4% and 17.3% in the intensive therapy group. In both treatment arms, the greatest 
adjusted RRs on the risk of subsequent SH episodes were also observed in the first 3 
months after the index SH compared to those without occurrence of the index of SH: in the 
conventional therapy group, the RRs and the 95% CI in the first 3 months, months 4-6 and 
7-9 were 3.38 (2.21, 5.18), 1.37 (0.76, 2.47) and 1.95 (1.33, 2.87) respectively, and the 
corresponding RRs were 1.7(1.48, 1.97), 1.45 (1.2, 1.74) and 1.36 (1.16, 1.61) in the 
intensive therapy group. Similar to RRs, the greatest risk differences (RDs) for the effects of 
index SH on subsequent episodes (calculated by transition probabilities) were also found in 
the 1st observation window after the index SH in both treatment groups. In summary, our 
results add to the empirical evidence for an acute effect of recent SH on subsequent 
episodes. It also indicates that the immediate periods after occurrences of SH are crucial in 
clinical management of type 1 diabetes to prevent subsequent SH.  
The first two parts of the study aim 2 was to estimate the effects of SH (index SH) on 
subsequent weight change/actual weight in various observation periods from 3, 6, 9, 12, 24 
and 36 months after index SH, and on weight change in other three fixed-term time windows 
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during months 1-3, 4-6 and 7-9 after index SH, respectively. In the intensive therapy arm, 
the estimated effects of index SH on subsequent weight change and weight appeared to be 
close to the null effect (zero for the difference of the means for weight change or for 
difference of the means for weight) comparing to those without index SH. However, in the 
conventional therapy group, a small weight loss was observed in the 1st 3-month period 
following SH (adjusted differences of the means for weight change were -0.29 (-0.51, -0.08)), 
but the estimated differences of the means for weight change were close to null in the 
subsequent 2nd time window (months 4-6) and the 3rd time window (months 7-9) following 
index SH. The last part of the study aim 2 was to estimate the HRs of occurrence of SH on 
time to substantial weight gain (defined as the 5, 10, 15 and 20% weight gain from the 
DCCT baseline), on becoming overweight, or on becoming obese, respectively. The 
estimated HRs of SH on time to substantial weight gain, becoming overweight or becoming 
obese were also found around the null effect (HR=1) in both treatment arms. In the intensive 
therapy group, the adjusted HRs were 0.94 (0.69, 1.3) and 1.07 (0.71, 1.64), respectively, 
for becoming overweight, and becoming obese following the first SH during follow-up; the 
corresponding HRs were 1.11 (0.71, 1.72) and 1.20 (0.52, 2.79) in the conventional therapy 
arm. The HRs obtained from Cox models and marginal structural models (MSM) were 
similar. We used MSM as an ancillary analysis to allow us to control for average daily insulin 
dose, which may be seen as a time-dependent confounder affected by prior SH. In summary, 
our study did not find evidence to support an association between occurrence of SH and 
subsequent weight gain in patients with type 1 diabetes. 
B. Strengths 
Our study utilized longitudinal information from the DCCT study accounting for 
repeated observations to estimate the acute effects of SH on risk of subsequent SH 
episodes in a clinically relevant time range. This approach has not been mentioned in any 
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relevant prior studies in literature. The similar designs were also used for the estimations of 
the association between the occurrence of SH and subsequent weight gain in various 
periods in this study.   
We designed our study to reserve the temporality of SH as a risk factor for 
subsequent weight gain, which has not been addressed by any previous studies either. As 
an ancillary analysis, we used marginal structural models (MSM) to control for average daily 
insulin dose, which may be seen as a time-dependent confounder affected by prior SH. To 
our knowledge, our study is the first one to systematically test the association between the 
occurrence of SH and subsequent weight gain using various study designs and analytic 
methods including the design for repeated observations, survival analysis and MSM models 
in a type 1 diabetic cohort. 
Last but not least, our study data (the DCCT data) were from one of the largest and 
longest follow-up type 1 diabetes cohorts up to today. The DCCT had well defined 
information for SH, which is the exposure and outcome variable for our study aim 1 and the 
exposure definition for the study aim 2. To be matter of fact, American Diabetes Association 
Workgroup on hypoglycemia adopted a same definition for SH as that in the DCCT [20].  
C. Limitations 
The daily changes of therapy regimens in the DCCT were not centrally documented 
and were not accessible for analysis. We only had quarterly data available for patients in our 
study and assumed that it was representative of the full quarter for individual patients. 
Information on activities that affect the risk for SH, including physical activity and alcohol 
consumption, was not available even quarterly, and we had to use annual collected 
information on physical activity and alcohol consumption as a surrogate for data for each 
quarterly visit. However, conventional risk factors for SH, including physical activity and 
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alcohol consumption, were reported to be well under control in the DCCT because a careful 
review for these factors was performed for the patient once SH occurred in a patient during 
the trial [10]. Because of limited information in the DCCT, we only can estimate the total 
effects of SH on subsequent SH episodes, and cannot disentangle underlying intermediate 
effects due to physicians and patients’ activities in responding the SH events (index SH) on 
subsequent SH episodes, and similarly, we also cannot disentangle underlying causal 
mechanisms (overreaction to SH by consuming more calories vs. other unknown 
mechanisms) due to limited diet and physical activity information for the association 
between SH and subsequent weight gain. Furthermore, in term of association between 
occurrence of hypoglycemia and weight gain, we were only able to study severe cases of 
hypoglycemia and we do not know whether our findings would apply to less severe episodes.  
   We should be cautious about extrapolating our findings to all patients with type 1 
diabetes because of the selected trial population and the trial design of the DCCT. Because 
the DCCT is a clinical trial, patients in the DCCT likely had greater medical surveillance, 
stricter diets and weight management compared with the patients in routine clinical care, 
and patients were likely to be more adherent to their medical and diet regiments as well [31]. 
D. Future directions 
1. Public health and clinical practice implication in study aim 1 
Our findings for acute effects of recent SH provide some evidence to support an 
American Diabetes Association (ADA) suggestion. According to this ADA suggestion, 
patients with recent SH episodes may benefit from at least a short-term relaxation of 
glycemic targets to reduce risk of recurrent SH [43]. However, this suggestion was mostly 
based on the studies which  only provided a proof of principle to use relaxation of glycemic 
targets as a potential intervention to reduce subsequent SH events, and they were 
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conducted in relatively small-scales under only a couple of patients and had insufficient 
follow-up duration to directly measure differences in SH [19]. Thus, more studies in future 
should be needed to examine the magnitudes and durations of various interventions in the 
time period immediately after recent SH (e.g., relaxation of glycemic targets and/or 
increasing glucose monitoring etc.) to assess optimal benefit and harm profiles to reduce 
both subsequent SH and other diabetic complications (e.g., micro-macrovascular diseases). 
2. Future research for study aim 2 
  In our analysis, we cannot disentangle underlying causal mechanisms (overreaction 
to SH by consuming more calories vs. other unknown mechanisms) due to limited diet 
information in the DCCT. Future studies should also consider examining the relationship 
between the occurrence of SH/hypoglycemia and subsequent diet change to directly 
address the assumed mechanism for the hypothesis of compensation for hypoglycemia.  
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